

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

CO

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 409/04, 411/04, 473/02 A61K 31/505, C07F 7/18	AI	(11) International Publication Number: WO 92/08717 (43) International Publication Date: 29 May 1992 (29.05.92)
(21) International Application Number: PCT/CA91/00407 (22) International Filing Date: 12 November 1991 (12.11.91) (30) Priority data: 612,840 13 November 1990 (13.11.90) US (71) Applicant: IAF BIOCHEM INTERNATIONAL INC. [CA/CA]; 2550 Daniel Johnson, Suite 600, Laval, Quebec H7T 2L1 (CA). (72) Inventors: BELLEAU, Bernard (deceased). BRASILL, Livio ; Via Medaglie D'Oro, 25, I-63023 Fermo (IT). NGUYEN-BA, Ngha ; 175 Place Leotable Dubuc, LaP-rainie, Quebec JSR 5M5 (CA). LAVAL, Chan, Chun, Kong ; 27 Levere Street, Kirkland, Quebec H9J 3X8 (CA).		(74) Agents: MORROW, Joy, D. et al.; Smart & Biggar, 900-55 Melcalfe Street, P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6 (CA). (81) Designated States: AT, AT (European patent), AU, BR, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU*, ID (OAPI patent), TG (OAPI patent). Published With international search report.

(54) Title: SUBSTITUTED 1,3-OXATHIOLANES AND SUBSTITUTED 1,3-DITHIOLANES WITH ANTIVIRAL PROPERTIES



(1)

(57) Abstract

This invention relates to novel substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes of formula (1) wherein X is S, S=O, or SO₂; Y is O, S, S=O, or SO₂; R₁ is hydrogen, trisubstituted silyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted C₁₋₁₆ acyl; and R₂ is a purine or pyrimidine base or an analogue or derivative thereof; and pharmaceutically acceptable derivatives thereof. This invention also relates to processes for preparing these compounds, intermediates useful in their preparation, to pharmaceutical compositions containing them and to the use of these compounds as antiviral agents.

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU*	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

WO 92/08717

PCT/CA91/00407

SUBSTITUTED 1,3-OXATHIOLANES
AND SUBSTITUTED 1,3-DITHIOLANES
WITH ANTIVIRAL PROPERTIES

The present invention relates to novel
5 substituted 1,3-oxathiolane and substituted 1,3-
dithiolane compounds having pharmacological activity, to
intermediates useful in their preparation, to pharma-
ceutical compositions containing them, and to the use of
these compounds in the antiviral treatment of mammals.

10 Retroviral infections are a serious cause of
disease, most notably, the acquired immunodeficiency
syndrome (AIDS). The human immunodeficiency virus (HIV)
has been recognized as the etiologic agent of AIDS.
Compounds having an inhibitory effect on HIV
15 multiplication or otherwise effective in the therapy of
retroviral infections are being actively sought.


H. Mitsuya et al., "3'-Azido-3'-deoxythymidine
(BW A509U): An antiviral agent that inhibits the
infectivity and cytopathic effect of human T-lymphotropic
20 virus type III/lymphadenopathy-associated virus in
vitro", Proc. Natl. Acad. Sci. U.S.A., 82, pp. 7096-7100
(1985), refers to 3'-azido-2',3'-dideoxythymidine of
formula (A), commonly referred to as AZT. This compound
is said to be useful in providing some protection for
25 AIDS carriers against the cytopathogenic effect of
immunodeficiency virus (HIV).

SUBSTITUTE SHEET

WO 92/08717


PCT/CA91/00407

2



(A)

H. Mitsuya and S. Broder, "Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides", Proc. Natl. Acad. Sci. U.S.A., 83, pp. 1911-15 (1986), have also referred to a group of 2',3'-dideoxynucleosides shown in formula (B) which are said to possess protective activity against HIV-induced cytopathogenicity.



(B)

P. Herdewijn et al., "3'-Substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV(HTLV-III/LAV) agents", J. Med. Chem., 30, pp. 1270-1278 (1987), describe the anti-HIV activity of a series of 3'-substituted nucleoside analogues. While 3'-fluoro analogues of 2',3'-dideoxythymidine and 2',3'-dideoxycytidine shown in formulas (C) and (D) are found to possess potent antiretroviral activity, substituents


SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407


3

linked to the 3'-carbon via a thio or oxygen bridge did not yield active products.



- Analysis of molecular conformation studies in
- 5 P. Van Roey et al., "Correlation between preferred sugar ring conformation and activity of nucleoside analogues against human immunodeficiency virus", Proc. Natl. Acad. Sci. U.S.A., 86(10), pp. 3929-3933 (1989), indicate that
- 10 active anti-HIV nucleoside analogues have 3' carbon conformations on the side opposite to the base.

- D. Huryn et al., "Synthesis of iso-ddA, member of a novel class of anti-HIV agents", Tetrahedron Lett., 30(46), pp. 6259-6262 (1989), refer to the iso-nucleoside analogue of formula (E) as a stable inhibitor of HIV
- 15 replication.



R. Vince and M. Hua, "Synthesis and anti-HIV activity of carbocyclic 2',3'-didehydro-2',3'-dideoxy


SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407


4

2,6-disubstituted purin nucleosides", J. Med. Chem.,
33(1), pp. 17-21 (1990), describe the analogues shown in
formulas (F) and (G) as having anti-HIV activity. The
unsaturated analogue (F) shows greater selectivity and
potency as an inhibitor of HIV replication than the
saturated analog (G).



C. Chu et al., "Synthesis and structure-
activity relationships of 6-substituted 2',3'-
dideoxypurine nucleosides as potential anti-human
immunodeficiency virus agents", J. Med. Chem., 33(6),
pp. 1553-1561 (1990), describe the N₆-methyl derivative
shown in formula (H) as having greater potency against
HIV than unmethylated 2',3'-dideoxyadenosine.

15



Finally, B. Belleau et al., "Design and
activity of a novel class of nucleoside analogues
effective against HIV-1", Abstracts of papers, Fifth
International Conference on AIDS, Montreal, T.C.O. 1,



SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

5

p. 515 (1989), refer to dioxolanes and oxathiolanes of formulas (J) and (K) as having potent anti-HIV activity.




5 Despite these developments to date, and in view of the increasing incidence and life threatening characteristics of AIDS, there is a great need for the discovery and development of new potent and non-toxic inhibitors of HIV.

10 Two structurally distinct classes of compounds known as 2-substituted 4-substituted 1,3-oxathiolanes and 2-substituted 4-substituted 1,3-dithiolanes have been found to have potent antiretroviral activity. In particular, these compounds have been found to act as

15 potent inhibitors of HIV-1 replication in T-lymphocytes over a prolonged period of time with less cytotoxic side effects than compounds known in the art. These compounds are also useful in prophylaxis and treatment of hepatitis B virus infections.

20 There are accordingly provided in a first aspect of this invention compounds of formula (I)



(I)

wherein X is S, S=O, or SO₂;

Y is O, S, S=O, or SO₂;

25 R₁ is hydrogen; and

SUBSTITUTE SHEET
ISA/EP



WO 92/08717

PCT/CA91/00407

6



R_2 is a purine or pyrimidin base or an analogue or derivative thereof; and pharmaceutically acceptable derivatives thereof.

It will be appreciated by those skilled in the art that the compounds of formula (I) contain at least two chiral centers (shown as * in formula (I)) and thus exist in the form of two pairs of optical isomers (i.e., enantiomers) and mixtures thereof including racemic mixtures. Thus the compounds of formula (I) may be either cis isomers, as represented by formula (II), or trans isomers, as represented by formula (III), or mixtures thereof. Each of the cis and trans isomers can exist as one of two enantiomers or as mixtures thereof including racemic mixtures. All such isomers and mixtures thereof including racemic mixtures are included within the scope of the invention.



The compounds of formula (I) are preferably in the form of their cis isomers.

It will also be appreciated that when X is S=O and Y is O, S, or SO₂, the compounds exist in two additional isomeric forms as shown in formulas (IIa) and (IIb). These isomers differ in the configuration of the oxide oxygen atom relative to the 2,4-substituent.


**SUBSTITUTE SHEET**

WO 92/08717

PCT/CA91/00407

7

It will be further appreciated that when X is S=O and Y is S=O the compounds exist in four additional isomeric forms as shown in formulas (IIc)-(IIf). These isomers differ in the configuration of the oxide oxygen atom relative to the 2,4-substituent. Similar isomeric forms exist for the trans compounds of formula (III).



The compounds of the invention additionally embrace such isomers and mixtures thereof.

The R_2 purine or pyrimidine base or analogue or derivative thereof, depicted in formula (I), will be linked at the 9- or 1- position respectively. By purine or pyrimidine base or analogue or derivative thereof is meant a purine or pyrimidine base found in native nucleosides or an analogue thereof which mimics such bases in that their structures (the kinds of atoms and their arrangement) are similar to the native bases but may either possess additional or lack certain of the functional properties of the native bases. Such analogues include those derived by replacement of a CH moiety by a nitrogen atom (for example, 5-azapyrimidines such as 5-azacytosine) or vice versa (for example, 7-deazapurines, such as 7-deazadenine or 7 deazaguanine) or both (e.g., 7-deaza, 8-azapurines). By derivatives of

SUBSTITUTE SHEET


WO 92/08717

8

PCT/CA91/00407

such bases or analogues are meant those compounds wherein ring substituents are either incorporated, removed, or modified by conventional substituents known in the art, e.g., halogen, hydroxyl, amino, C₁₋₆ alkyl. Such purine or pyrimidine bases, analogues and derivatives will be well known to those skilled in the art.


Conveniently the group R₂ is selected from:

**SUBSTITUTE SHEET**

WO 92/08717

PCT/CA91/00407

9




SUBSTITUTE SHEET

WO 92/08717

10

PCT/CA91/00407



wherein R_3 is selected from the group of hydrogen, C_{1-10} acyl (e.g., acetyl), hydroxyl, substituted or unsubstituted C_{1-6} alkyl, and substituted or unsubstituted C_{1-6} alkenyl or alkynyl (e.g. propynyl);

5 R_4 and R_5 are independently selected from the group of hydrogen, hydroxymethyl, trifluoromethyl, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{1-6} alkenyl or alkynyl, bromine, chlorine, fluorine, iodine, and thioaryl;

10 R_6 is selected from the group of hydrogen, bromine, chlorine, fluorine, iodine, cyano, carboxy, carboxamide, ethoxycarbonyl, carbamoyl, and thiocarbamoyl;

15 R_7 and R_8 are independently selected from the group of hydrogen, bromine, chlorine, fluorine, iodine, substituted or unsubstituted amino, and hydroxy; and

SUBSTITUTE SHEET

WO 92/08717


11

PCT/CA91/00407

R_9 is selected from the group of hydrogen, C_{1-10} acyl, hydroxyl, substituted or unsubstituted C_{1-6} alkyl, and substituted or unsubstituted C_{1-6} alkenyl or alkynyl; and pharmaceutically acceptable derivatives.

5

Preferably R_2 is




wherein R_7 and R_8 are as defined above.

Y is preferably -O-.

The preferred 2-substituted 4-substituted 1,3-oxathiolane of this invention is a compound of formula

10 (Ia):






(Ia)

wherein X is S, S=O, or SO_2 ;

R_1 is hydrogen,; and

preferably, R_2 is a heterocyclic radical selected from the group consisting of:




SUBSTITUTE SHEET

WO 92/08717

12

PCT/CA91/00407



wherein R₃ is selected from the group of hydrogen, C₁₋₁₀ acyl (e.g., acetyl), hydroxyl, substituted or unsubstituted C₁₋₆ alkyl, and substituted or unsubstituted C₁₋₆ alkenyl or alkynyl (e.g. propynyl);

SUBSTITUTE SHEET.

WO 92/08717

PCT/CA91/00407

13


R_4 and R_5 are independently selected from the group of hydrogen, hydroxymethyl, trifluoromethyl, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{1-6} alkenyl or alkynyl, bromine, chlorine, fluorine, iodine, and thioaryl;

R_6 is selected from the group of hydrogen, bromine, chlorine, fluorine, iodine, cyano, carboxy, carboxamide, ethoxycarbonyl, carbamoyl, and thiocarbamoyl;

R_7 and R_8 are independently selected from the group of hydrogen, bromine, chlorine, fluorine, iodine, substituted or unsubstituted amino, and hydroxy; and

R_9 is selected from the group of hydrogen, C_{1-10} acyl, hydroxyl, substituted or unsubstituted C_{1-6} alkyl, and substituted or unsubstituted C_{1-6} alkenyl or alkynyl; and pharmaceutically acceptable derivatives.

The preferred 2-substituted 4-substituted 1,3-dithiolane of this invention is a compound of formula (Ib):






(Ib)

wherein each X is independently selected from the group consisting of S, S=O, and SO₂;

R_1 is hydrogen; and

preferably, R_2 is a heterocyclic radical selected from the group consisting of:

















SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

14



SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

15

wherein R_3 is selected from the group of hydrogen, C_{1-10} acyl (e.g., acetyl), hydroxyl, substituted or unsubstituted C_{1-6} alkyl, and substituted or unsubstituted C_{1-6} alkenyl or alkynyl (e.g. propynyl);

5 R_4 and R_5 are independently selected from the group of hydrogen, hydroxymethyl, trifluoromethyl, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{1-6} alkenyl or alkynyl, bromine, chlorine, fluorine, iodine, and thioaryl;

10 R_6 is selected from the group of hydrogen, bromine, chlorine, fluorine, iodine, cyano, carboxy, carboxamide, ethoxycarbonyl, carbamoyl, and thiocarbamoyl;

R_7 and R_8 are independently selected from the group of hydrogen, bromine, chlorine, fluorine, iodine, substituted or unsubstituted amino, and hydroxy; and

15 R_9 is selected from the group of hydrogen, C_{1-10} acyl, hydroxyl, substituted or unsubstituted C_{1-6} alkyl, and substituted or unsubstituted C_{1-6} alkenyl or alkynyl; and pharmaceutically acceptable derivatives.

20 As used herein, the term "acyl" refers to a radical derived from a carboxylic acid, substituted or unsubstituted, by replacement of the -OH group. Like the acid to which it is related, an acyl radical may be aliphatic or aromatic, substituted or unsubstituted, and whatever the structure of the rest of the molecule may be, the properties of the functional group remain essentially the same. The use of the term "aroyl" is meant to refer to acyl groups derived from aromatic acids and describes a preferred subset of the term "acyl".

25 30 Other suitable acyl groups will include, for example: acetyl, propionyl, isobutanoyl, pivaloyl, hexanoyl, trifluoroacetyl, chloroacetyl, cyclohexanoyl, chlorobenzoyl, methoxybenzoyl, trifluoromethylbenzoyl, 1-naphthaloyl, 2-naphthaloyl, phenacyl, nitrobenzoyl,

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

16

α -hydroxy- α -phenylacetyl, α -methoxy- α -phenylacetyl, aminoacetyl, α -amino- β -phenylpropionyl, and α -methoxy- α -(trifluoromethyl) phenacyl.

As used herein, "a pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, ester, or salt of such ester, of a compound of formula (I) or any other compound which, upon administration to the recipient, is capable of providing (directly or indirectly) a compound of formula (I) or an antivirally active metabolite or residue thereof.

Pharmaceutically acceptable salts of the compounds of formula (I) include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(C₁₋₄ alkyl)₄⁺ salts.

References hereinafter to a compound according to the invention include both compounds of formula (I) and their pharmaceutically acceptable derivatives.

It will be appreciated by those skilled in the art that the compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof, at functional groups in both the base moiety, R₂, and at the hydroxymethyl group of the oxathiolane or dithiolane ring. Modification at all such functional groups is

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

17

included within the scope of the invention. However, of particular interest are pharmaceutically acceptable derivatives (e.g., esters or esters of amino acids) obtained by modification of the 2-hydroxymethyl group of the oxathiolane or dithiolane ring.

Preferred esters of the compounds of formula (I) include the compounds in which R_1 is replaced by a carboxyl function $R-\overset{\overset{O}{\parallel}}{C}$ in which the non-carbonyl moiety R of the ester grouping is selected from hydrogen, straight or branched chain alkyl (e.g., methyl, ethyl, n-propyl, t-butyl, n-butyl), alkoxyalkyl (e.g., methoxymethyl), aralkyl (e.g., benzyl), aryloxyalkyl (e.g., phenoxymethyl), aryl (e.g., phenyl optionally substituted by halogen, C_{1-4} alkyl or C_{1-4} alkoxy); substituted dihydro pyridinyl (e.g., N-methyldihydro pyridinyl); sulphonate esters such as alkyl- or aralkylsulphonyl (e.g., methanesulphonyl); sulfate esters; amino acid esters (e.g., L-valyl or L-isoleucyl) and mono-, di- or tri-phosphate esters.

Also included within the scope of such esters are esters derived from polyfunctional acids such as carboxylic acids containing more than one carboxyl group, for example, dicarboxylic acids $HO_2C(CH_2)_nCO_2H$ where n is an integer of 1 to 10 (for example, succinic acid) or phosphoric acids. Methods for preparing such esters are well known. See, for example, E. Hahn et al., "Nucleotide dimers as anti-human immunodeficiency virus agents", Nucleotide Analogues As Antiviral Agents, J.C. Martin, Ed. Symposium Series #401, American Chemical Society, pp. 156-159 (1989) and M. Busso et al., "Nucleotide dimers suppress HIV expression in vitro", AIDS Research and Human Retroviruses, 4(6), pp. 449-455 (1988). Where esters are derived from such acids, each acidic group is preferably esterified by a compound of formula (I) or other nucleosides or analogues and


SUBSTITUTE SHEET
ISAVEP

WO 92/08717

PCT/CA91/00407

18

derivatives thereof to provide esters of the formula (IV) where:



(IV)

W is $-\text{O}-\overset{\text{O}}{\parallel}{\text{C}}-(\text{CH}_2)_n-\overset{\text{O}}{\parallel}{\text{C}}-\text{O}-$ and n is an integer of 1 to 10

5 or $-\text{O}-\overset{\text{O}}{\parallel}{\text{P}}(\text{O}^-)-\text{O}-$ or $-\text{O}-\overset{\text{S}}{\parallel}{\text{P}}(\text{O}^-)-\text{O}-$, J is any nucleoside or

nucleoside analogue or derivative thereof and X, Y, and R_2 are as defined above. Among the preferred nucleosides and nucleoside analogues are 3'-azido-2',3'-dideoxy-thymidine, 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 10 2',3'-dideoxyinosine, 2',3'-dideoxythymidine, 2',3'-dideoxy-2',3'-didehydrothymidine, and 2',3'-dideoxy-2',3'-didehydrocytidine and ribavirin and those nucleosides whose bases are depicted on pages 7-8 of this specification. The preferred ester of this invention is 15 a homodimer consisting of two nucleosides of formula (I).

With regard to the above described esters, unless otherwise specified, any alkyl moiety present advantageously contains 1 to 16 carbon atoms, preferably 1 to 4 carbon atoms and could contain one or more double 20 bonds. Any aryl moiety present in such esters advantageously comprises a phenyl group.

In particular the esters may be a C_{1-16} alkyl ester, an unsubstituted benzoyl ester or a benzoyl ester substituted by at least one halogen (bromine, chlorine, 25 fluorine or iodine), C_{1-6} alkyl or alkenyl, saturated or unsaturated C_{1-6} alkoxy, nitro or trifluoromethyl groups.

Specific compounds of formula (I) include:

cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(cytosin-1'-yl)-

SUBSTITUTE SHEET
ISA/EP

WQ 92/08717

PCT/CA91/00407

19

1,3-oxathiolane, and mixtures thereof;

cis-2-hydroxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;

5 cis-2-hydroxymethyl-4-(uracil-1'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(uracil-1'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-hydroxymethyl-4-(thymine-1'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(thymine-1'-yl)-1,3-oxathiolane, and mixtures thereof;

10 cis-2-hydroxymethyl-4-(6'-chloropurin-9'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(6'-chloropurin-9'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-hydroxymethyl-4-(adenine-9'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(adenine-9'-yl)-1,3-oxathiolane, and mixtures thereof;

15 cis-2-hydroxymethyl-3-oxo-4-(adenine-9'-yl)-1,3-oxathiolane;

cis-2-hydroxymethyl-4-(6'-N-methylamino-purin-9'-yl)-1,3-oxathiolane;

20 cis-2-hydroxymethyl-4-(6'-N,N-dimethylamino-purin-9'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(6'-N,N-dimethylamino-purin-9'-yl)-1,3-oxathiolane, and mixtures thereof;

25 cis-2-hydroxymethyl-4-(2'-amino-6'-chloro-purin-9'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(2'-chloro-amino-6'-purin-9'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-hydroxymethyl-4-(2',6'-diamino-purin-9'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(2',6'-diamino-purin-9'-yl)-1,3-oxathiolane, and mixtures thereof;

30 cis-2-hydroxymethyl-4-(guanine-9'-yl)-1,3-oxathiolane;

cis-2-hydroxymethyl-4-(cytosine-1'-yl)-1,3-dithiolane, trans-2-hydroxymethyl-4-(cytosine-1'-yl)-1,3-dithiolane, and mixtures thereof;

SUBSTITUTE SHEET

WO 92/08717

20

PCT/CA91/00407

cis-2-hydroxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-dithiolane, trans-2-hydroxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-dithiolane, and mixtures thereof; and pharmaceutically acceptable derivatives thereof in the form of a racemic mixture or single enantiomer.

Preferred compounds of formula (I) are cis-2-hydroxymethyl-4-(adenin-9'-yl)-1,3-oxathiolane and pharmaceutically acceptable derivatives thereof in the form of a racemic mixture or single enantiomer.

In the processes for preparing the compounds of this invention, the following definitions are used:

R₂ is a purine or pyrimidine base or an analogue or derivative thereof;

R_w is hydrogen, trisubstituted silyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted aralkyl such as benzyl or trityl, substituted or unsubstituted C₁₋₁₆ acyl, preferably a benzoyl or a benzoyl substituted in any position by at least one halogen (bromine, chlorine, fluorine or iodine), C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, or trifluoromethyl group;

R_x is substituted or unsubstituted C₁₋₆ alkyl; and

L is a "leaving group", i.e., an atom or group which is displaceable upon reaction with an appropriate base, with or without a Lewis acid. Suitable leaving groups include acyloxy groups, alkoxy groups, e.g., alkoxy carbonyl groups such as ethoxy carbonyl; halogens such as iodine, bromine, chlorine, or fluorine; amido; azido; isocyanato; substituted or unsubstituted, saturated or unsaturated thiolates, such as thiomethyl or thiophenyl; substituted or unsubstituted, saturated or unsaturated selenino compounds, such as phenyl selenide or alkyl selenide; and substituted or unsubstituted, saturated or unsaturated aliphatic or aromatic ketones such as methyl ketone.

A suitable leaving group may also be -OR, where R is a substituted or unsubstituted, saturated or unsaturated

SUBSTITUTE SHEET


WO 92/08717

PCT/CA91/00407

21

alkyl group, e.g., C₁₋₆ alkyl or alkenyl group; a substituted or unsubstituted aliphatic or aromatic acyl group, e.g., a C₁₋₆ aliphatic acyl group such as acetyl and an aromatic acyl group such as benzoyl; a substituted or unsubstituted, saturated or unsaturated alkoxy or aryloxy carbonyl group, such as methyl carbonate and phenyl carbonate; substituted or unsubstituted sulphonyl imidazolidine; substituted or unsubstituted aliphatic or aromatic amino carbonyl group, such as phenyl carbamate; substituted or unsubstituted alkyl imide group such as trichloroacetamide; substituted or unsubstituted, saturated or unsaturated phosphonates, such as diethylphosphonate; substituted or unsubstituted aliphatic or aromatic sulphonyl group, such as tosylate; or hydrogen.


Oxathiolane compounds of formula (Ia),



(Ia)

wherein X is S, S=O, or SO₂, and their pharmaceutically acceptable derivatives, may be prepared according to the processes discussed herein or by any method known in the art for the preparation of compounds of analogous structure.

In one such process for producing oxathiolanes of this invention, a compound of formula (V),



(V)

SUBSTITUTE SHEET


WO 92/08717

PCT/CA91/00407

22

wherein R_w is hydrogen or a hydroxyl protecting group and L is a displaceable atom or group, i.e., a leaving group, is reacted with an appropriate base.

In a second process for producing oxathiolanes of this invention, a compound of formula (VI)



(VI)

may be converted to a compound of formula (Ia) by conversion of the anomeric NH_2 group to the required base by methods well known in the art of nucleoside chemistry.

The 1,3-oxathiolanes of formula (Ia) may also be prepared, for example, by reaction of an aldehyde of formula (VII)



(VII)

with 2-mercaptoethanol in a compatible organic solvent followed by Pummerer rearrangements as is known in the art (T. Durst, "Dimethylsulfoxide in Organic Synthesis", Adv. Org. Chem., E.C. Taylor and B. Wynberg, Eds., 6, pp. 356-365 (1969)) to give 1,3-oxathiolanes of formula (V), which are converted to 1,3-oxathiolanes of formula (Ia) by methods known in the art of nucleoside chemistry.


Another process for preparing the 1,3-oxathiolanes of formula (Ia) is illustrated in SCHEME 1. Although this process is illustrated using specific reagents and compounds, it will be appreciated by one of skill in the art that suitable analogous reactants may be used to prepare analogous products, as depicted, for example, in SCHEME 1A.

SUBSTITUTE SHEET

WO 92/08717

23

PCT/CA91/00407


SCHEME 1

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

24

SCHEME 1A

SUBSTITUTE SHEET

WO 92/08717

25

PCT/CA91/00407

The various steps involved in the synthesis of 1,3-oxathiolanes of formula (Ia) as illustrated in SCHEME 1 may be briefly described as follows:

Step 1: Benzoyloxyacetaldehyde of formula (VII) or any aldehyde of the formula R_wOCH_2CHO (C.D. Hurd and E.M. Filiachione, "A new approach to the syntheses of aldehyde sugars", J. Am. Chem. Soc., 61, pp. 1156-1159 (1939)) is condensed with a mercaptoalcohol such as 2-mercaptoethanol in a compatible organic solvent, such as toluene, containing a catalytic amount of a strong acid to give the intermediate shown in formula (VIII).

Step 2: The 1,3-oxathiolane of formula (VIII) is then oxidized with a peracid such as magnesium monoperoxyphthalic acid in a compatible organic solvent such as methylene chloride containing a salt such as tetrabutyl ammonium bromide to give the sulfoxide intermediate shown in formula (IX).

Step 3: The sulfoxide intermediate shown in formula (IX) is treated with an acid anhydride such as acetic anhydride or any other anhydride of the formula $(R_x)_2O$ in the presence of a buffer such as tetra-n-butylammonium acetate to give the 2,4-disubstituted-1,3-oxathiolane of formula (X) (T. Durst, Adv. Org. Chem., 6, pp. 356-365 (1969)).

Step 4: The 1,3-oxathiolane of formula (X) is then reacted with a pyrimidine or purine base or analogue thereof, (e.g., 6-chloropurine) previously silylated with, for example, hexamethyldisilazane in a compatible solvent using a Lewis acid or trimethylsilyl triflate to give the intermediate of formula (XI) as cis and trans isomers. The isomers may be separated, preferably by chromatography, to give pure cis (XI) and pure trans (XI).

Step 5: The benzoate function of the compound of formula (XI) (cis or trans isomer), is hydrolyzed

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

26

using a base such as methanolic ammonia to obtain the compound shown in formula (XII) as cis- or trans- isomer.

Step 6: The chloro function of product of formula (XII) is displaced by methanolic ammonia


5 preferably under pressure to give the product shown in formula (XIII) as a cis- or trans- isomer.

Step 7: The preceding isomers of formula (XIII) are treated with an oxidizing agent, e.g., a suitable peracid, in a compatible organic solvent to give
10 the 3-oxide (sulfoxide) of formula (XIV).

Step 8: The chloro function of the compound of formula (XII) is displaced by ethanolic methylamine, preferably under pressure, to give the product shown in
15 formula (XV) as a cis- or trans- isomer.

Step 9: The chloro function of the compound of formula (XII) is displaced by ethanolic dimethylamine, preferably under pressure, to give the product shown in
20 formula (XVI) as a cis- or trans- isomer.

Dithiolane compounds of formula (Ib),



(Ib)

wherein each X is independently selected from S, S=O, or SO₂, and their pharmacologically acceptable derivatives, may be prepared according to the processes discussed herein or by any method known in the art for the
25 preparation of compounds of analogous structure.

In one such process for preparing the dithiolanes of this invention, a compound of formula (XVII)

SUBSTITUTE SHEET


SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

29

SCHEME 2




SUBSTITUTE SHEET.

WO 92/08717

30

PCT/CA91/00407


SCHEME 2A

SUBSTITUTE SHEET

WO 92/08717

27


PCT/CA91/00407



(XVII)

wherein R_w is hydrogen or hydroxyl protecting group and L is a displaceable atom or group, i.e., a leaving group, is reacted with an appropriate base.

5 In another process for preparing the dithiolanes of this invention, a compound of formula (XVIII)



(XVIII)

10 may be converted to a compound of formula (Ib) by conversion of the anomeric NH_2 group to the required base by methods well known in the art of nucleoside chemistry.

The 1,3-dithiolanes of formula (Ib) may also be prepared, for example, by reaction of an aldehyde of formula (VII)

15



(VII)

with 1,2-ethanedithiol in a compatible organic solvent followed by Pummerer rearrangement as is known in the art (T. Durst, Adv. Org. Chem., 6, p. 356-365 (1969)) to give 1,3-dithiolanes of formula (XVII) which are converted to 1,3-dithiolanes of formula (Ib) by methods known in the art of nucleoside chemistry.

Another process for preparing the 1,3-dithiolanes of formula (Ib) is illustrated in SCHEME 2. Although this process is illustrated using specific

SUBSTITUTE SHEET

SUBSTITUTE SHEET

WO 92/08717

31

PCT/CA91/00407

The various steps involved in the synthesis of 1,3-dithiolanes of formula (Ib) as illustrated in SCHEME 2 may be briefly described as follows:

5 Step 1: Benzoyloxyacetaldehyde of formula (VII) or any aldehyde of the formula R_wOCH_2CHO (C.D. Hurd and E.M. Filiachione, "A new approach to the synthesis of aldehyd sugars", J. Am. Chem. Soc., 61, pp. 1156-1159 (1939)) is condensed with a vicinal dithiol such as 1,2-
10 thanedithiol in a compatible organic solvent, such as toluene, containing a catalytic amount of a strong acid to give the intermediate shown in formula (XIX).

10 toluene, containing a catalytic amount of a strong acid
to give the intermediate shown in formula (XIX).

Step 2: The 1,3-dithiolane of formula (XIX) is
then oxidized with a peracid, such as m-chloroperoxybenzoic
acid in a compatible organic solvent, such as methylene
15 chloride to give the sulfoxide intermediate shown in
formula (XX).

Step 3: The sulfoxide intermediate shown in
formula (XX) is treated with an acid anhydride, such as
acetic anhydride or any other anhydride of the formula
20 $(R_x)_2O$, in the presence of a base, such as sodium
acetate, to give the 2,4-disubstituted-1,3-dithiolane of
formula (XXI) (T. Durst, Adv. Org. Chem., 6, pp. 356-365
(1969)).

Step 4: The 1,3-dithiolane of formula (XXI) is
25 then reacted with a pyrimidine or purine base or analogue
thereof containing an NH_2 group (e.g., cytosine)
previously silylated with, for example, hexamethyl-
disilazane, in a compatible solvent using a Lewis acid,
such as tin IV tetrachloride or trimethylsilyl triflate,
30 to give the intermediate of formula (XXII) as cis and
trans isomers.

Step 5: The amine function of the compound
shown in formula (XXII) is acetylated with acetic
anhydride to yield the intermediate of formula (XXIII) as
35 cis and trans isomers which are separated, preferably by

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

32

chromatography, to give pure cis (XXIII) and pure trans (XXIII).

5 Step 6: The cis and trans isomers of formula (XXIII) are treated with methanolic ammonia to obtain the desired product shown in formula (XXIV) as a cis or trans isomer.

10 Another process for preparing the compounds of formula (Ib) is illustrated in SCHEME 3. Although this process is illustrated using specific reagents and compounds, it will be appreciated by one of skill in the art that suitable analogous reactants may be used to prepare analogous products, as depicted, for example, in SCHEME 3A.

SUBSTITUTE SHEET

WO 92/08717

28

PCT/CA91/00407

reagents and compounds, it will be appreciated by one of skill in the art that suitable analogous reactants may be used to prepare analogous products, as depicted, for example, in SCHEME 2A.

SUBSTITUTE SHEET.

MAY 08 '97 12:26


614 447 3648

PAGE.72

WO 92/08717

34

PCT/CA91/00407

SCHEME 3A

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

35

The various steps involved in the synthesis of 1,3-dithiolanes of formula (Ib) as illustrated in SCHEME 3 may be briefly described as follows:

Step 1: The known mercaptothioacetic acid of formula (XXV) (S. Satsumahyashi et al., "The Synthesis of 1,3-Dithiolanone Derivatives", *J. Org. Chem.*, 38, pp. 3953-3954 (1973) is reacted with an appropriate aldehyde of formula R_wOCH_2CHO , wherein R_w is preferably a silyl protecting group and more preferably, R_w is a t-butyldiphenylsilyl protecting group, in a compatible solvent, in the presence of an appropriate Lewis acid such as zinc iodide to give the intermediate of formula (XXVII).

Step 2: The compound of formula (XXVII) is reduced with an appropriate reducing agent such as diisobutylaluminum hydride in a compatible organic solvent such as toluene to give the compound of formula (XXVIII).

Step 3: The compound of formula (XXVIII) is reacted with an acid anhydride or acid chloride such as acetic anhydride in the presence of pyridine and an acylation catalyst such as dimethylaminopyridine to give the compound of formula (XXIX).

Step 4: The 1,3-dithiolane of formula (XXIX) is then reacted with a pyrimidine or purine base (e.g., cytosine) or analogue thereof previously silylated with, for example, hexamethyldisilazane in a compatible organic solvent using a Lewis acid, such as tin IV tetrachloride to give the intermediate of formula (XXX) as cis and trans isomers.

Step 5: The cis and trans isomers of formula (XXX) are treated with tetra n-butylammonium fluoride or other desilylating agents in an appropriate organic solvent such as tetrahydrofuran to give the desired product (XXIV) as a cis and trans isomers.

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

36

The cis and trans isomers of formula (XXIV) are separated preferably by high pressure liquid chromatography to obtain the desired 1,3-dithiolane of formula (Ib) as a pure cis or trans isomer.

5 Many of the reactions in the above-described processes have been extensively reported in the context of purine nucleoside synthesis, for example, in L.B. Townsend, "Chemistry of the heterocyclic moiety of purine nucleosides and some closely related analogues",
10 Nucleoside Analogues - Chemistry, Biology, and Medical Applications, R.T. Walker et al., Eds., Plenum Press, New York (1979) at pages 193-223, the text of which is incorporated by reference herein.

15 It will be appreciated that the reactions of the above-described processes may require the use of, or conveniently may be applied to, starting materials having protected functional groups, and deprotection might thus be required as an intermediate or final step to yield the desired compound. Protection and deprotection of
20 functional groups may be effected using conventional means. Thus, for example, amino groups may be protected by a group selected from aralkyl (e.g., benzyl), acyl or aryl (e.g., 2,4-dinitrophenyl); subsequent removal of the protecting group being effected when desired by
25 hydrolysis or hydrogenolysis as appropriate using standard conditions. Hydroxyl groups may be protected using any conventional hydroxyl protecting group, for example, as described in "Protective Groups in Organic Chemistry", Ed. J.F.W. MComie (Plenum Press, 1973) or
30 "Protective Groups in Organic Synthesis" by Theodora W. Greene (John Wiley and Sons, 1981). Examples of suitable hydroxyl protecting groups include groups selected from alkyl (e.g., methyl, t-butyl or methoxymethyl), aralkyl (e.g., benzyl, diphenylmethyl or triphenylmethyl),
35 heterocyclic groups such as tetrahydropyranyl, acyl, (e.g., acetyl or benzoyl) and silyl groups such as

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

37

trialkylsilyl (e.g., t-butyldimethylsilyl). The hydroxyl protecting groups may be removed by conventional techniques. Thus, for example, alkyl, silyl, acyl and heterocyclic groups may be removed by solvolysis, e.g.,
5 by hydrolysis under acidic or basic conditions. Aralkyl groups such as triphenylmethyl may similarly be removed by solvolysis, e.g., by hydrolysis under acidic conditions. Aralkyl groups such as benzyl may be
10 cleaved, for example, by treatment with BF_3 /etherate and acetic anhydride followed by removal of acetate groups so formed at an appropriate stage in the synthesis. Silyl groups may also conveniently be removed using a source of fluoride ions such as tetra-n-butylammonium fluoride.

In the above-described processes, the compounds
15 of formula (I) are generally obtained as a mixture of the cis and trans isomers.

These isomers may be separated, for example, by acetylation, e.g., with acetic anhydride followed by separation by physical means, e.g., chromatography on
20 silica gel and deacetylation, e.g., with methanolic ammonia or by fractional crystallization.

Pharmaceutically acceptable salts of the compounds of the invention may be prepared as described in United States Patent No. 4,383,114, the disclosure of
25 which is incorporated by reference herein. Thus, for example, when it is desired to prepare an acid addition salt of a compound of formula (I), the product of any of the above procedures may be converted into a salt by treatment of the resulting free base with a suitable acid
30 using conventional methods. Pharmaceutically acceptable acid addition salts may be prepared by reacting the free base with an appropriate acid optionally in the presence of a suitable solvent such as an ester (e.g., ethyl acetate) or an alcohol (e.g., methanol, ethanol or
35 isopropanol). Inorganic basic salts may be prepared by reacting the free base with a suitable base such as an

SUBSTITUTE SHEET

WO 92/08717

38

PCT/CA91/00407

alkoxide (e.g., sodium methoxide) optionally in the presence of a solvent such as an alcohol (e.g., methanol). Pharmaceutically acceptable salts may also be prepared from other salts, including other



- 5 pharmaceutically acceptable salts, of the compounds of formula (I) using conventional methods.

A compound of formula (I) may be converted into a pharmaceutically acceptable phosphate or other ester by reaction with a phosphorylating agent, such as POCl_3 , or
 10 a suitable esterifying agent, such as an acid halide or anhydride, as appropriate. An ester or salt of a compound of formula (I) may be converted to the parent compound, for example, by hydrolysis.

Where the compound of formula (I) is desired as
 15 a single isomer it may be obtained either by resolution of the final product or by stereospecific synthesis from isometrically pure starting material or any convenient intermediate.

Resolution of the final product, or an
 20 intermediate or starting material therefore may be effected by any suitable method known in the art: see for example, Stereochemistry of Carbon Compounds, by E.L. Eliel (McGraw Hill, 1962) and Tables of Resolving Agents, by S.H. Wilen.

25 The intermediates of formulas (Ic) and (Id) are useful in the above-described processes for making the oxathiolane and dithiolane compounds of this invention



wherein R_w is trisubstituted silyl, substituted or
 30 unsubstituted C_{1-6} alkyl, substituted or unsubstituted

SUBSTITUTE SHEET

WO 92/08717

39

PCT/CA91/00407

aralkyl such as benzyl or trityl, substituted or unsubstituted C₁₋₁₆ acyl, preferably a benzoyl or a benzoyl substituted in any position by at least one halogen (bromine, chlorine, fluorine or iodine), C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, or trifluoromethyl group; and
5 R₂ is a purine or pyrimidine base or an analogue or derivative thereof; and

L is a leaving group as previously defined.

The following intermediates of formula (Ic) are
10 of particular importance:

cis-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;
15

cis-2-benzoyloxymethyl-4-(uracil-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(uracil-1'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-4-(thymine-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(thymine-1'-yl)-1,3-oxathiolane, and mixtures thereof;
20

cis-2-benzoyloxymethyl-4-(6'-chloropurin-9'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(6'-chloropurin-9'-yl)-1,3-oxathiolane, and mixtures thereof;
25

cis-2-benzoyloxymethyl-4-(adenine-9'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(adenine-9'-yl)-1,3-oxathiolane;

cis-2-benzoyloxymethyl-4-(2'-amino-6'-chloro-purin-9'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(2'-amino-6'-chloro-purin-9'-yl)-1,3-oxathiolane, and mixtures thereof;
30

cis-2-benzoyloxymethyl-4-(cytosine-1'-yl)-1,3-dithiolane, trans-2-benzoyloxymethyl-4-(cytosine-1'-yl)-1,3-dithiolane, and mixtures thereof;
35

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

40

cis-2-benzoyloxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-dithiolan, trans-2-benzoyloxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-dithiolane, and mixtures thereof;

5 cis-2-t-butyldiphenylsilyloxymethyl-4-(cytosin-1'-yl)-1,3-dithiolane, trans-2-t-butyldiphenylsilyloxymethyl-4-(cytosin-1'-yl)-1,3-dithiolane, and mixtures thereof; and

10 cis-2-t-butyldiphenylsilyloxymethyl-4-(N₄'-acetoxy-cytosin-1'-yl)-1,3-dithiolane, trans-2-t-butyldiphenylsilyloxymethyl-4-(N₄'-acetoxy-cytosin-1'-yl)-1,3-dithiolane, and mixtures thereof.

The following intermediates of formula (Id) are of particular importance:

2-benzoyloxymethyl-1,3-oxathiolane;
15 cis-2-benzoyloxymethyl-1-oxo-1,3-oxathiolane, trans-2-benzoyloxymethyl-1-oxo-1,3-oxathiolane, and mixtures thereof;

20 cis-2-benzoyloxymethyl-4-acetoxy-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-acetoxy-1,3-oxathiolane, and mixtures thereof;

2-t-butyldiphenylsilyloxymethyl-1,3-dithiolane;
2-benzoyloxymethyl-1,3-dithiolane;
25 cis-2-benzoyloxymethyl-3-oxo-1,3-dithiolane, trans-2-benzoyloxymethyl-3-oxo-1,3-dithiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-4-acetoxy-1,3-dithiolane, trans-2-benzoyloxymethyl-4-acetoxy-1,3-dithiolane, and mixtures thereof;

30 cis-2-t-butyldiphenylsilyloxymethyl-4-hydroxy-1,3-dithiolane, trans-2-t-butyldiphenylsilyloxymethyl-4-hydroxy-1,3-dithiolane, and mixtures thereof; and

cis-2-t-butyldiphenylsilyloxymethyl-4-acetoxy-1,3-dithiolane, trans-2-t-butyldiphenylsilyloxymethyl-4-acetoxy-1,3-dithiolane, and mixtures thereof.

35 The compounds of the invention either themselves possess antiviral activity and/or are

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

41

5 metabolizable to such compounds. In particular these compounds are effective in inhibiting the replication of hepatitis B virus and retroviruses, including human retroviruses such as human immunodeficiency viruses (HIV's), the causative agents of AIDS.

10 There is thus provided as a further aspect of the invention a compound formula (I) or a pharmaceutically acceptable derivative thereof for use as an active therapeutic agent in particular as an antiviral agent, for example in the treatment of hepatitis B viral and retroviral infections.

15 In a further or alternative aspect there is provided a method for the treatment of a viral infection, in particular an infection caused by hepatitis B virus or a retrovirus such as HIV, in a mammal, including man, comprising administration of an effective amount of an antiviral compound of formula (I) or a pharmaceutically acceptable derivative thereof.

20 There is also provided in a further or alternative aspect of this invention, use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment of a viral infection.

25 The compounds of the invention are also useful in the treatment of AIDS-related conditions such as AIDS-related complex (ARC), persistent generalized lymphadenopathy (PGL), AIDS-related neurological conditions (such as dementia), anti-HIV antibody-positive and HIV-positive conditions, Kaposi's sarcoma, thrombocytopenia purpura and opportunistic infections.

30 The compounds of the invention are also useful in the prevention or progression to clinical illness of individuals who are anti-HIV antibody or HIV-antigen positive and in prophylaxis following exposure to HIV.

35 The compounds of formula (I) or the pharmaceutically acceptable derivatives thereof, may also

SUBSTITUTE SHEET
ISA/EP

WQ 92/08717

PCT/CA91/00407

42

be used for the prevention of viral contamination of biological fluids such as blood or semen in vitro.

Certain of the compounds of formula (I) are also useful as intermediates in the preparation of other compounds of the invention.

It will be appreciated by those skilled in the art that references herein to treatment extends to prophylaxis as well as the treatment of established infections or symptoms.

It will be further appreciated that the amount of a compound of the invention required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general, however, a suitable dose will be in the range from about 1 to about 750 mg/kg of body weight per day, such as 3 to about 120 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.

The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.

The compound is conveniently administered in unit dosage form; for example containing 10 to 1500 mg, conveniently 20 to 1000 mg, most conveniently 50 to 700 mg of active ingredient per unit dosage form.

Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 1 to 75 μM , preferably about 2 to 50 μM , most preferably about 3 to about 30 μM . This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

43

ingredient, optionally in saline, or administered as a bolus containing about 0.1 to about 110 mg/kg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical formulation.

The invention thus further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers thereof and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

Pharmaceutical formulations suitable for oral administration may conveniently be presented as discrete units such as capsules, cact ts or tablets each

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

44

containing a predetermined amount of the active ingredient; as a powder or granules; as a solution; as a suspension; or as an emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

- 5 Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of,
10 for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents,
15 emulsifying agents, non-aqueous vehicles (which may include edible oils) or preservatives.

- The compounds according to the invention may also be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous
20 infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and
25 may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle,
30 e.g., sterile, pyrogen-free water, before use.

- For topical administration to the epidermis, the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for
35 example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

45

ag nts. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.

Formulations suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavored based, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Pharmaceutically formulations suitable for rectal administration wherein the carrier is a solid, are most preferably represented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in molds.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient, such carriers as are known in the art to be appropriate.

For intra-nasal administration the compounds of the invention may be used as a liquid spray or dispersible powder or in the form of drops.

Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilizing agents or suspending agents. Liquid sprays are conveniently delivered from pressurized packs.

For administration by inhalation, the compounds according to the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray.

SUBSTITUTE SHEET

WO 92/08717

46

PCT/CA91/00407

Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount.

Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges or, e.g., gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.

When desired, the above described formulations adapted to give sustained release of the active ingredient, may be employed.

The pharmaceutical compositions according to the invention may also contain other active ingredients such as antimicrobial agents, or preservatives.

The compounds of the invention may also be used in combination with other therapeutic agents, for example, other anti-infective agents. In particular the compounds of the invention may be employed together with known antiviral agents.

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a physiologically acceptable derivative thereof together with another therapeutically active agent, in particular, an antiviral agent.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

47

together with a pharmaceutically acceptable carrier
thereof comprising a further aspect of the invention.

Suitable therapeutic agents for use in such combinations include acyclic nucleosides such as
5 acyclovir, ganciclovir, interferons such as alpha-, beta-
and gamma-interferon; glucuronation inhibitors such as
probenecid; nucleoside transport inhibitors such as
dipyridamole; nucleoside analogues such as 3'-azido-
2',3'-dideoxythymidine, 2',3'-dideoxycytidine, 2',3'-
10 dideoxyadenosine, 2',3'-dideoxyinosine, 2',3'-
dideoxythymidine, 2',3'-dideoxy-2',3'-didehydro-
thymidine, and 2',3'-dideoxy-2',3'-didehydrocytidine and
ribavirin; immunomodulators such as interleukin II (IL2)
and granulocyte macrophage colony stimulating factor (GM-
15 CSF), erythropoietin, amphotericin, thymomodulin,
thymopentin, foscarnet, glycosylation inhibitors such as
2-deoxy-D-glucose, castanospermine, 1-deoxynojirimycin;
and inhibitors of HIV binding to CD4 receptors such as
soluble CD4, CD4 fragments and CD4-hybrid molecules.

20 The individual components of such combinations
may be administered either sequentially or simultaneously
in separate or combined pharmaceutical formulations.

When the compound of formula (I) or a
pharmaceutically acceptable derivative thereof is used in
25 combination with a second therapeutic agent active
against the same virus, the dose of each compound may be
either the same or differ from that when the compound is
used alone. Appropriate doses will be readily
appreciated by those skilled in the art.

30 The invention will be further described by the
following examples which are not intended to limit the
invention in any way. All temperatures are in degrees
celsius.

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

48

EXAMPLESExample 1Benzoyloxyacetaldehyde

(VII)

5 This known intermediate was prepared by
portionwise addition of NaIO_4 (80 g) to a mixture of 1-
benzoyl glycerol (50 g), CH_2Cl_2 (500 ml), and H_2O (25 ml)
under vigorous stirring at room temperature. The
resulting solution was stirred for 2 hours MgSO_4 (100 g)
10 added, and the solution stirred for an additional 30
minutes. The mixture was filtered, the filtrate
evaporated in vacuo and the residue distilled in vacuo to
yield 26 g of pure product.


b.p. 92-94°/0.25 mm

15 ^1H NMR (200 MHz ; TMS as internal reference): δ (ppm in CDCl_3)9.71 (s, 1H; $-\text{CHO}$)

8.11 (d, 2H; aromatic)

7.60 (m, 1H; aromatic)

20 7.46 (m, 2H; aromatic)

4.88 (s, 2H; $-\text{CH}_2\text{CHO}$)Example 22-Benzoyloxymethyl-1,3-oxathiolane

(VIII)

25 A mixture of benzoyloxyacetaldehyde (6.21 g), 2-
mercaptoethanol (3 ml) and para-toluene sulfonic acid

SUBSTITUTE SHEET

WO 92/08717

49

PCT/CA91/00407

(0.2 g) in toluene (150 ml) was heated for 3 h urs at refluxing under water removal conditions using a Dean Stark apparatus. The mixture was cooled to room temperature, washed first with aqueous NaHCO_3 -solution (1 x 50 ml), and then with water (2.5 ml) and dried over MgSO_4 . The solution was filtered and the filtrate evaporated under reduced pressure. The residue was purified on silica gel using hexane:ethyl acetate (9:1) as eluant. It yielded 7.63 g (90%) of pure product, which was identified by ^1H - and ^{13}C -NMR.

R_f : 0.39 (hexane:ethyl acetate)

^1H -NMR: δ (ppm in CDCl_3)

8.03 (m, 2H, aromatic)

7.53 (m, 1H, aromatic)

7.39 (m, 2H, aromatic)

5.41 (dd, 1H, C_2 -H)

4.43 (m, 2H, C_2 - $\text{CH}_2\text{OCC}_6\text{H}_5$)

4.21 (m, 1H, C_5 -H)

3.96 (m, 1H, C_5 -H)


2.98 (m, 2H, C_4 -H)

^{13}C -NMR: δ (ppm in CDCl_3)

166.82, 133.74, 130.35, 128.97, 83.58, 71.87, 66.62 and 32.74

Example 3

25 2-Benzoyloxymethyl-3-oxo-1,3-oxathiolane



(IX)

Monoperoxyphthalic acid, magnesium salt (MMPP, 28 g) was added portion wise under vigorous stirring to a

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

50

mixture of 2-benzoyloxymethyl-1,3-oxathiolan (20 g), tetrabutyl ammonium bromide (0.4 g) in methylene chloride (200 ml), and water (200 ml). The mixture was stirred at room temperature for 30 minutes and the organic layer was collected. The aqueous phase was extracted with methylene chloride (3 x 75 ml) and the combined organic layer was washed first with water (2 x 100 ml), then with brine solution (100 ml), dried over $MgSO_4$, and filtered. The filtrate was evaporated in vacuo and the residue was purified by chromatography on silica gel using ethyl acetate as eluant to give 18.5 g (86%) of pure product as a mixture of cis- and trans- isomers in a ratio of 1:2. m.p.: 70-72°

1H -NMR: δ (ppm in $CDCl_3$)

- 15 8.05 (m, 2H, aromatic, cis-isomer)
 7.95 (m, 2H, aromatic, trans-isomer)
 7.56 (m, aromatic)
 7.23 (m, aromatic)
 4.77 (m, 4H, C_2 -H, C_5 -H, and C_2 - CH_2OOC C_6H_5)
20 4.43 (m, 1H, C_5 -H, trans-isomer)
 4.09 (m, 1H, C_5 -H, cis-isomer)
 3.11 (m, 2H, C_4 -H, trans-isomer)
 2.75 (m, 2H, C_4 -H, cis-isomer)

^{13}C -NMR: δ (ppm in $CDCl_3$)

25 cis-isomer:

 166.64, 134.02, 130.42, 129.88, 129.06, 96.16,
 68.83, 59.47 and 54.30

trans-isomer:


- 30 166.36, 134.12, 130.29, 129.68, 129.15, 108.07,
 70.09, 61.83 and 53.47

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

51

Example 42-Benzoyloxymethyl-4-acetoxy-1,3-oxathiolane

(X)

A mixture of 2-benzoyloxymethyl-3-oxo-1,3-oxathiolane (10.5 g), tetra-n-butylammonium acetate (17 g) in acetic anhydride (250 ml) was heated at 110'-120°C under argon for 14 hours and cooled to room temperature. Excess acetic anhydride was removed under reduced pressure. The residue was dissolved in methylene chloride (500 ml), washed first with saturated aqueous NaHCO₃ (2 x 200 ml), then with brine solution (200 ml), dried over MgSO₄, filtered and evaporated in vacuo. The residue was purified by chromatography on silica gel using hexane:ethyl acetate (8:1) as eluant to give 7.4 g (60% yield) of the desired product as a mixture of cis- and trans- isomers. A small quantity of each isomer was also isolated and characterized by ¹H- and ¹³C-NMR.

cis-isomer:R_F: 0.43 (hexane:EtOAc)¹H-NMR: δ(ppm in CDCl₃)

8.05 (m, 2H, aromatic)

7.58 (m, 1H, aromatic)

7.45 (m, 2H, aromatic)

6.24 (d, 1H, C₄-H)25 5.50 (t, 1H, C₂-H)4.61 (d, 1H, C₂-CH₂OOC-C₆H₅)4.53 (d, 2H, C₅-H)3.94 (dd, 1H, C₅-H)2.05 (s, 3H, CH₃)

SUBSTITUTE SHEET


WO 92/08717

PCT/CA91/00407

52

trans-isomer: R_f : 0.43 (hexane:EtOAc 7:3) $^1\text{H-NMR}$: δ (ppm in CDCl_3)

- 5 8.04 (m, 2H, aromatic)
7.58 (m, 1H, aromatic)
7.45 (m, 2H, aromatic)
6.27 (dd, 1H, $\text{C}_4\text{-H}$)
5.73 (dd, 1H, $\text{C}_2\text{-H}$)
4.53 (dd, 1H, $\text{C}_2\text{-CH}_2\text{OCC}_6\text{H}_5$)
10 4.34 (dd, 1H, $\text{C}_5\text{-H}$)
4.26 (dd, 1H, $\text{C}_2\text{-CH}_2\text{OCC}_6\text{H}_5$)
4.20 (dd, 1H, $\text{C}_5\text{-H}$)
2.09 (s, 3H, CH_3)
 $^{13}\text{C-NMR}$: δ (ppm in CDCl_3)
15 177.66, 166.37, 133.46, 129.93, 128.60, 83.76,
81.22, 74.33, 64.65 and 20.79

Example 5cis- and trans-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane

- 25 A mixture of cytosine (206 mg), ammonium sulfate (10 mg) and hexamethyldisilazane (HMDS, 10 ml) was heated at refluxing under argon until a clear solution resulted. Excess reagents were evaporated in vacuo and the remaining volatile removed under high vacuum (15 minutes). The solid residue was dissolved in dry methylene chloride (20 ml) and a solution of 2-benzoyloxymethyl-4-acetoxy-1,3-oxathiolane (350 mg) in dry methylene chloride (20 ml) was added under argon,

SUBSTITUTE SHEET

WO 92/08717


PCT/CA91/00407

53

followed by a solution of tin IV chloride (SnCl_4 , 124 ml) in methylene chloride (20 ml) at 0°C. The reaction mixture was stirred under argon overnight at room temperature, then heated at refluxing for 3 hours and cooled to room temperature. The mixture was diluted with methylene chloride (100 ml) and poured while stirring into saturated aqueous NaHCO_3 . The organic layer was separated by filtration over celite, washed first with water (2 x 75 ml), then with brine solution (100 ml), dried over MgSO_4 and filtered. The residue was purified by chromatography on silica gel using ethyl acetate: CH_3OH as the eluant to give 140 mg (35%) of the desired product as a mixture of cis- and trans- isomers in a 1:1 ratio as determined by $^1\text{H-NMR}$. These isomers were separated as the N-acetyl derivatives in the next example.

Example 6

Cis- and trans-2-benzoyloxymethyl-4-(N₄, -acetyl-cytosin-1'-yl)-1,3-oxathiolane



A solution of the cis- and trans- mixture of 2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane (135 mg), 4-dimethylaminopyridine (DMAP, 15 mg) and acetic anhydride (44 ml) in dry pyridine (10 ml) was stirred overnight at room temperature (16 hours) and poured into cold water (100 ml) followed, by extraction with methylene chloride (3 x 50 ml). The extract was washed with water, dried over MgSO_4 , filtered and

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

54

evaporated in vacuo. Toluene was added to the residue, then evaporated in vacuo. Toluene was added to the residue, then evaporated in vacuo and the residual oil was purified by chromatography on silica gel using ethyl acetate as eluant to yield 65 mg of pure trans-isomer as the fast moving product and 60 mg of pure cis-isomer as the low moving product. These were characterized by ^1H and ^{13}C -NMR.

cis-isomer:10 ^1H -NMR: δ (ppm in CDCl_3)9.61 (b, 1H, C_4 , $-\text{NHCOCH}_3$)8.29 (d, 1H, C_6 , $-\text{H}$)

8.06 (m, 2H, aromatic)

7.65 (m, 1H, aromatic)

15 7.51 (m, 2H, aromatic)

7.25 (d, 1H, C_5 , $-\text{H}$)6.61 (d, 1H, C_4 -H)5.50 (t, 1H, C_2 -H)4.80 (m, 2H, C_2 - $\text{CH}_2\text{OOCCH}_5$)20 4.48 (d, 1H, C_5 -H)4.05 (dd, 1H, C_5 -H)2.25 (s, 3H, CH_3) ^{13}C -NMR: δ (ppm in CDCl_3)

170.93, 166.28, 162.80, 155.76, 146.06, 133.91,

25 129.90, 128.84, 97.45, 85.88, 78.25, 64.60, 63.53

and 24.71.

trans-isomer: ^1H -NMR: δ (ppm in DMSO-d_6)10.88 (s, 1H, C_4 , $-\text{NHCOCH}_3$)30 8.13 (d, 1H, C_6 , $-\text{H}$)

7.96 (m, 2H, aromatic)

7.68 (m, 1H, aromatic)

7.52 (m, 2H, aromatic)

7.20 (d, 1H, C_5 , $-\text{H}$)35 6.35 (d, 1H, C_4 -H)5.96 (dd, 1H, C_2 -H)

SUBSTITUTE SHEET

WO 92/08717


PCT/CA91/00407

55

- 4.58 (dd, 1H, C₂-CH₂OOCC₆H₅)
 4.44 (d, 1H, C₅-H)
 4.29 (m, 2H, C₅-H and CH₂OOCC₆H₅)
 2.07 (s, 3H, CH₃)
- 5 ¹³C-NMR: δ(ppm in DMSOd₆)
 171.53, 165.84, 162.76, 155.21, 146.59, 134.00,
 129.64, 129.23, 96.54, 83.78, 74.24, 64.58, 64.01
 and 24.35

Example 7

- 10 cis- and trans-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-
oxathiolane



(XXXIII)

cis-isomer:

- 15 A solution of cis-2-benzoyloxymethyl-4(N₄,
 acetyl-cytosin-1'-yl)-1,3-oxathiolane (54 mg) in
 methanolic ammonia (50 ml) was stirred overnight at room
 temperature (16 hours). The solvent was evaporated in
 vacuo and the residue treated with ether yielding 37 mg
 20 (90%) of desired product. The product was then
 characterized by ¹H- and ¹³C-NMR.

m.p.: 213-215°C

UV: (CH₃OH) Lambda max: 270 nm¹H-NMR: δ(ppm in, DMSOd₆)

- 25 7.85 (d, 1H, C₆, -H)
 7.16 (d, 2H, C₄, -NH₂)
 6.34 (d, 1H, C₄-H)
 5.76 (d, 1H, C₅, -H)

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

56

5.31 (t, 1H, C₂-CH₂OH)
5.18 (t, 1H, C₂-H)
4.40 (d, 1H, C₅-H)
3.92 (dd, 1H, C₅-H)
5 3.78 (m, 2H, C₂-CH₂OH)
¹³C-NMR: δ(ppm in DMSO-d₆)
165.95, 155.74, 142.39, 94.98, 88.85, 77.29, 62.91
and 62.48

trans-isomer:

10 A solution of trans-2-benzoyloxymethyl-4-(N₄,
acetyl-cytosin-1'-yl)-1,3-oxathiolane (63 mg) in
methanolic ammonia (50 ml) was stirred overnight at room
temperature (16 hours). The solvent was removed in vacuo
and the residue was solidified with ether to give 36 mg
15 (93%) of the desired product which was characterized by
¹H- and ¹³C-NMR.

m.p.: 175-177°C

UV: (CH₃OH) λ_{max}: 270 nm


¹H-NMR: δ(ppm in DMSO-d₆)
20 7.67 (d, 1H, C₆-H)
7.19 (d, 2H, C₄-NH₂)
6.30 (d, 1H, C₄-H)
5.77 (d, 1H, C₅-H)
5.56 (t, 1H, C₂-CH₂OH)
25 5.23 (t, 1H, C₂-H)
4.18 (m, 2H, C₅-H)
3.61 (m, 1H, C₂-CH₂OH)
3.36 (m, 1H, C₂-CH₂OH)
¹³C-NMR: δ(ppm in DMSO-d₆)
30 166.00, 155.65, 142.30, 95.11, 87.52, 74.52, 63.42
and 62.86

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

57

Example 8Cis- and trans-2-benzoyloxymethyl-4(uracil-1'-yl)-1,3-oxathiolane

(XXXIV)

5 A mixture of uracil (446 mg), ammonium sulfate (20 mg) and hexamethyldisilazane (HMDS, 15 ml) was heated at refluxing under argon until the solution became clear (3 hours). Excess HMDS was removed under reduced pressure and the residue was dried under high vacuum for 3 hours. The oily residue was dissolved in dry methylene chloride (20 ml) and a solution of 2-benzoyloxymethyl-4-acetoxy-1,3-oxathiolane (748 mg) in dry methylene chloride (15 ml). The reaction mixture was stirred overnight at room temperature (20 hours) then poured into saturated aqueous NaHCO₃-solution (100 ml). The organic layer was collected and the aqueous phase was extracted with methylene chloride (2 x 50 ml). The combined organic phase was washed with water, dried over MgSO₄, filtered and evaporated under reduced pressure. The residue was purified and separated by chromatography on silica gel using hexane:ethyl acetate (1:4) as eluant. It gave 258 mg (29%) of a fast moving product, which was identified as trans-isomer and 156 mg (18%) of a low moving product, which was identified as cis-isomer.

25 cis-isomer:

¹H-NMR: δ(ppm in DMSO-d₆)

11.39 (s, 1H, N₃-H)

8.00 (d, 2H, aromatic)

7.97 (m, 2H, C₆-H and aromatic)

SUBSTITUTE SHEET

WO 92/08717

58

PCT/CA91/00407

- 7.56 (m, 2H, aromatic)
6.31 (d, 1H, C₄-H)
5.53 (t, 1H, C₂-H)
5.41 (d, 1H, C₅-H)
5 4.76 (d, 2H, C₂-CH₂OH)
4.65 (d, 1H, C₅-H)
4.01 (dd, 1H, C₅-H)

¹³C-NMR: δ (ppm in DMSO-d₆).

- 165.83, 163.36, 151.06, 141.25, 134.15, 129.72,
10 129.50, 129.29, 102.83, 85.34, 76.60, 63.78 and
62.68

trans-isomer:

¹H-NMR: δ (ppm in CDCl₃)


- 9.10 (b, 1H, N₃-H)
15 8.02 (d, 2H, aromatic)
7.53 (m, 2H, C₆-H and aromatic)
7.43 (m, 2H, aromatic)
6.50 (d, 1H, C₄-H)
5.87 (dd, 1H, C₂-H)
20 5.76 (d, 1H, C₅-H)
4.56 (dd, 1H, C₂-CH₂OBz)
4.30 (m, 2H, C₅-H)
4.24 (dd, 1H, C₂-H₂OBz)

¹³C-NMR: δ (ppm in CDCl₃)

- 25 166.28, 163.49, 150.89, 140.70, 133.59, 129.87,
129.42, 128.64, 103.72, 84.18, 75.18, 64.24 and
62.23

Example 9

30 Cis-and trans-2-hydroxymethyl-4-(uracil-1'-yl)-1,3-
oxathiolane



(XXV)

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

59

cis-is mer:

A solution of cis-2-benzoyloxymethyl-4-(uracil-1'-yl)-1,3-oxathiolane (150 mg) in methanolic ammonia (50 ml) was stirred overnight at room temperature (16 hours). Solvent was evaporated in vacuo and the residue was triturated with ether (2 x 10 ml) and crystallized in ethyl acetate to yield 77 mg (75%) of desired product which was characterized by spectroscopic methods.

10 m.p.: 138-140°C

UV: (CH₃OH) Lamda max: 266 nm¹H-NMR: δ(ppm in DMSO-d₆)11.36 (s, 1H, N₃-H)7.88 (d, 1H, C₆-H)15 6.28 (d, 1H, C₄-H)5.66 (d, 1H, C₅-H)5.39 (t, 1H, C₂-CH₂OH)5.19 (t, 1H, C₂-H)4.55 (d, 1H, C₅-H)20 3.95 (dd, 1H, C₅-H)3.80 (m, 2H, C₂-CH₂OH)¹³C-NMR: δ(ppm in DMSO-d₆).163.54, 151.13, 141.87, 102.63, 89.13, 77.15, 62.45
and 62.0425 trans-isomer:

A solution of trans-2-benzoyloxymethyl-4-(uracil-1'-yl)-1,3-oxathiolane (207 mg) in methanolic ammonia (50 ml) was stirred overnight at room temperature (16 hours) and then evaporated in vacuo. The residue was treated with ether (2 x 20 ml) and filtered. The solid residue was washed with cold ethyl acetate and yield 115 mg (81%) of pure product which was characterized by ¹H- and ¹³C-NMR.

m.p.: 176-178°C

35 UV: (CH₃OH) Lamda max: 266 nm¹H-NMR: δ(ppm in DMSO-d₆)

SUBSTITUTE SHEET

WO 92/08717


PCT/CA91/00407

60

- 11.39 (s, 1H, N₃-H)
 7.66 (d, 1H, C₆-H)
 6.25 (d, 1H, C₄-H)
 5.67 (d, 1H, C₅-H)
 5
 5.62 (dd, 1H, C₂-H)
 5.27 (t, 1H, C₂-CH₂OH)
 4.35 (d, 1H, C₅-H)
 4.16 (dd, 1H, C₅-H)
 3.60 (m, 1H, C₂-CH₂OH)
 10
 3.35 (m, 1H, C₂-CH₂OH)
¹³C-NMR: δ(ppm in DMSO-d₆)
 163.53, 151.15, 141.77, 102.78, 87.77, 74.28, 63.25
 and 62.32

Example 10

- 15 cis- and trans-2-benzoyloxymethyl-4-(thymine-1'-yl)-1,3-
oxathiolane



(XXXVI)

- A mixture of thymine (671 mg), ammonium sulfate
 (20 mg) and hexamethyldisilazane (HMDS, 20 ml) was heated
 20 at refluxing until the solution became clear (3 hours).
 Excess reagent was evaporated in vacuo and the remaining
 volatile removed under high vacuum (1 hour). The oily
 residue was dissolved in dry methylene chloride (20 ml)
 and a solution of 2-benzoyloxymethyl-4-acetoxy-1,3-
 25 oxathiolane (1.05 g) in dry methylene chloride (20 ml)
 was added under argon, followed by a solution of
 trimethylsilyl trifluoromethane sulfonate (865 ml) in

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

61

methylen chloride (5 ml). The reaction mixture was stirred overnight at room temperature under argon (16 hours) and poured into saturated aqueous NaHCO_3 -solution. The organic layer was separated and the aqueous phase extracted with methylen chloride (3 x 50 ml). The combined organic layer was washed with water (2 x 50 ml). The combined organic layer was washed first with water (2 x 50 ml), then with brine solution (100 ml), dried over MgSO_4 , filtered and evaporated in vacuo. The residue was purified and separated by chromatography on silica gel using hexane:ethyl acetate (1:1) as eluant to give 732 mg of a fast moving product which was identified by spectroscopic methods as trans-isomer and 244 mg of a lower moving product which was identified as cis-isomer. Total yield was 976 mg (75%).

cis-isomer: $^1\text{H-NMR}$: δ (ppm in DMSO-d_6)

11.41 (s, 1H, N_3 , -H)
7.98 (d, 2H, aromatic)
7.72 (t, 1H, aromatic)
7.53 (t, 2H, aromatic)
7.47 (s, 1H, C_6 , -H)
6.32 (d, 1H, C_2 -H)
4.73 (m, 3H, C_5 -H and C_2 - $\text{CH}_2\text{OCC}_6\text{H}_5$)
4.01 (dd, 1H, C_5 -H)
1.58 (s, 3H, CH_3)

 $^{13}\text{C-NMR}$: δ (ppm in DMSO-d_6)

165.89, 164.00, 151.08, 136.37, 134.09, 129.63,
110.73, 85.30, 75.99, 63.68, 62.58 and 12.18

trans-isomer: $^1\text{H-NMR}$: δ (ppm in CDCl_3)

8.30 (s, 1H, N_3 , -H)
8.04 (d, 2H, aromatic)
7.58 (t, 1H, aromatic)
7.45 (t, 2H, aromatic)
7.32 (d, 1H, C_6 , -H, $J = 1.3$ Hz)

SUBSTITUTE SHEET


WO 92/08717

62

PCT/CA91/00407

- 6.50 (dd, 1H, C₄-H)
 5.90 (dd, 1H, C₂-H)
 4.58 (dd, 1H C₂-CH₂OCC₆H₅)
 4.30 (m, 2H, C₅-H)
 5 4.24 (dd, 1H, C₂-CH₂OOCC₆H₅)
 1.91 (d, 3H, -CH₃, J = 1.1 Hz)
¹³C-NMR: δ(ppm in CDCl₃)
 166.29, 163.91, 150.95, 136.14, 133.59, 129.88,
 128.58, 112.48, 84.16, 75.04, 64.29, 62.35 and 12.41

10 Example 11
Cis- and trans-2-hydroxymethyl-4-(thymin-1'-yl)-1,3-
oxathiolane



(XXXVII)

cis-isomer:

- 15 A solution of cis-2-benzoyloxymethyl-4-(thymin-1'-yl)-1,3-oxathiolane (190 mg) in saturated methanolic ammonia was stirred overnight at room temperature (16 hours). The mixture was evaporated under reduced pressure and the residue was purified by chromatography
 20 on silica gel using ethyl acetate as eluant to give 109 mg (82%) of pure product.

m.p.: 149-151°C

UV: (CH₃OH) λ_{max}: 271.3 nm

¹H-NMR: δ(ppm in DMSO-d₆)

- 25 11.37 (s, 1H, N₃-H, D₂O-exchange).
 7.79 (d, 1H, C₆-H, J = 1.1 Hz)
 6.30 (d, 1H, C₄-H, J = 4.4 Hz)

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

63

- 5.44 (t, 1H, C₂-CH₂OH, D₂O-exchange)
5.20 (t, 1H, C₂-H, J = 4.2 Hz)
4.52 (d, 1H, C₅-H, J = 10.7 Hz)
3.93 (dd, 1H, C₅-H, J = 4.90 and 10.7 Hz)
5 3.81 (m, 2H, C₂-CH₂OH)
1.78 (s, 3H, -CH₃)
¹³C-NMR: δ(ppm in DMSO-d₆)
164.15, 151.08, 137.44, 110.14, 89.09, 67.17, 62.18,
61.89 and 12.37

10 trans-isomer:

- A mixture of trans-2-benzoyloxymethyl-4-(thymine-1'-yl)-1,3-oxathiolane (200 mg) in saturated methanolic ammonia (50 ml) was stirred overnight at room temperature (16 hours). The mixture was evaporated under
15 reduced pressure and the residue was triturated with diethyl ether (3 x 15 ml) and filtered. The solid residue was recrystallized in ethanol to give 136 mg (97%) of pure product.

m.p.: 202-204°C

- 20 UV: (CH
- ₃
- OH) Lambda max: 271.3 nm

- ¹H-NMR: δ(ppm in DMSO-d₆)
11.40 (s, 1H, N₃-H, D₂O exchange)
7.49 (s, 1H, C₆-H)
6.26 (d, 1H, C₄-H)
25 5.67 (dd, 1H, C₂-H)
5.27 (t, 1H, C₂-CH₂OH, D₂O-exchange)
4.32 (d, 1H, C₅-H)
4.16 (dd, 1H, C₅-H)
3.58 (dd, 1H, C₂-CH₂OH)
30 3.33 (dd, 1H, C₂-CH₂OH)
1.80 (s, 3H, CH₃)


- ¹³C-NMR: δ(ppm in DMSO-d₆)
164.04, 150.90, 136.92, 110.44, 87.68, 74.06, 63.18,
61.98 and 12.19

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

64

Example 12Cis- and trans-2-benzoyloxymethyl-4-(6-chloropurin-9'-yl)-1,3-oxathiolane

- 5 A mixture of 6-chloropurine (850 mg), ammonium sulfate (20 mg) and hexamethyldisilazane (HMDS, 20 ml) was heated at refluxing until the solution became clear. Excess reagent was evaporated in vacuo and the remaining volatile removed under high vacuum (1 hour). The oily
- 10 residue was dissolved in dry dichloroethane (50 ml) and a solution of 2-benzoyloxymethyl-4-acetoxy-1,3-oxathiolane (1 g) in dry dichloroethane (20 ml) was added under argon, followed by a solution of trimethylsilyl trifluoromethane sulfonate (825 ml) in dry dichloroethane
- 15 (5 ml). The mixture was heated at refluxing under argon for 2 hours, cooled to room temperature and poured into saturated aqueous NaHCO₃ solution. The organic layer was collected and the aqueous phase was extracted with methylene chloride (3 x 70 ml). The combined organic
- 20 layer was washed first with water (2 x 50 ml), then with brine solution, dried over MgSO₄ and filtered. The filtrate was evaporated under reduced pressure and the residue was purified by chromatography on silica gel using hexane:ethyl acetate (1:1) as eluant to give 435 mg
- 25 of fast moving product which was identified as trans-isomer and 245 mg of lower moving product which was identified as cis-isomer. The total yield was 51%. Each isomer was characterized by ¹H- and ¹³C-NMR spectroscopy.

SUBSTITUTE SHEET

WO 92/08717

65

PCT/CA91/00407

cis-isomer:¹H-NMR: δ (ppm in CDCl₃)

- 5 8.73 (s, 1H, C₈-H)
8.53 (s, 1H, C₂-H)
8.02 (d, 2H, aromatic)
7.56 (m, 1H, aromatic)
7.45 (m, 2H, aromatic)
6.51 (d, 1H, C₄-H, J = 3.8 Hz)
5.62 (t, 1H, C₂-H, J = 4.8 Hz)
10 4.78 (m, 2H, C₂-CH₂OOC C₆H₅)
4.69 (d, 1H, C₅-H, J = 10.4 Hz)
4.18 (dd, 1H, C₅-H, J = 4.0 and 10.6 Hz)

¹³C-NMR: δ (ppm in CDCl₃)


- 15 165.83, 152.24, 151.80, 149.63, 145.48, 134.07,
129.58, 129.21, 85.42, 76.84, 64.48, and 61.75

trans-isomer:¹H-NMR: δ (ppm in CDCl₃)

- 20 8.74 (s, 1H, C₈-H)
8.38 (s, 1H, C₂-H)
8.05 (d, 2H, aromatic)
7.58 (m, 1H, aromatic)
7.45 (m, 2H, aromatic)
6.50 (d, 1H, C₄-H, J = 3.7 Hz)
6.03 (dd, 1H, C₂-H)
25 4.70 (dd, 1H, C₂-CH₂OOC C₆H₅)
4.50 (m, 2H, C₅-H)
4.32 (dd, 1H, C₂-CH₂OOC C₆H₅)

Example 13

30 Cis-2-hydroxymethyl-4-(6'-chloropurin-9-yl)-1,3-oxathiolane



(XII)

SUBSTITUTE SHEET

WO 92/08717


PCI/CA91/00407

66

- A solution of cis-2-benzoyloxymethyl-4-(6'-chlor purin-9'-yl)-1,3-oxathiolane (300 mg) in methanolic ammonia (40 ml) was stirred overnight at room temperature (16 hours). The solvent was evaporated under reduced pressure and the residue was purified by chromatography on silica gel using EtOAc:MeOH (95:5) as eluant to give 189 mg (88%) of the desired product.
- m.p.: 175-176°C
- R_f: 0.68 (EtOAc:MeOH)
- UV: (H₂O) Lambda Max 263.5 nm
- H-NMR: δ (ppm in DMSO-d₆)
- 9.07 (s, 1H, C₈-H)
 - 8.98 (s, 1H, C₂-H)
 - 6.70 (d, 1H, C₄-H)
 - 5.61 (t, 1H, C₂-CH₂OH, D₂O-exchange)
 - 5.53 (t, 1H, C₂-H)
 - 4.90 (d, 1H, C₅-H)
 - 4.27 (dd, 1H, C₅-H)
 - 4.02 (m, 2H, C₂-CH₂OH)
- ¹³C-NMR: δ (ppm in DMSO-d₆)
- 152.17, 151.59, 149.58, 146.07, 131.17, 80.04, 77.37, 62.02, and 61.31

Example 14

- Cis- and trans-2-hydroxymethyl-4-(adenin-9'-yl)-1,3-oxathiolane



(XIII)

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

67

cis-isomer:

A mixture of cis-2-benzoyl xymethyl-4-(6-chloropurin-9'-yl)-1,3-oxathiolane (140 mg) in saturated ethanolic ammonia (50 ml) was placed in a steel bomb and heated overnight at 100-110°C (16 hours). The bomb was cooled to room temperature and emptied. The mixture was evaporated under reduced pressure and the residue was purified by chromatography on silica gel using ethyl acetate:methanol (85:5) as eluant to give 70 mg (71%) of pure product.

m.p.: 200-202°C

UV: (CH₂OH) Lambda max: 260 nm¹³H-NMR: δ(ppm in DMSO-d₆)

8.31 (s, 1H, C₈-H)
8.16 (s, 1H, C₂-H)
7.31 (s, 2H, C₆-NH₂, D₂O-exchange)
6.36 (d, 1H, C₄-H, J = 3.8 Hz)
5.41 (t, 1H, C₂-H, J = 3.8 Hz)
5.34 (t, 1H, C₂-CH₂OH, D₂O-exchange)
4.66 (d, 1H, C₅-H, J = 11.4 Hz)
4.09 (dd, 1H, C₅-H, J = 4.1 and 10.4 and 10.4 Hz)
3.83 (m, 2H, C₂-CH₂OH)

¹³C-NMR: δ(ppm in DMSO-d₆)

156.51, 153.09, 149.45, 139.19, 118.76, 89.06,
77.65, 62.79 and 60.13

trans-isomer:

A mixture of trans-2-benzoyloxymethyl-4-(6'-chloropurin-9'-yl)-1,3-oxathiolane (220 mg) in saturated ethanolic ammonia (50 ml) was placed in a steel bomb and heated overnight at 110°C for overnight (16 hours). The bomb was cooled to room temperature and emptied. The mixture was evaporated under reduced pressure and the residue was purified by chromatography on silica gel using EtOAc:MeOH (95:5) as eluant to give 76 mg (50%) the desired product.

m.p.: 185-187°C

SUBSTITUTE SHEET

WO 92/08717


PCT/CA91/00407

68

UV: (CH₃OH) λ_{max} : 260 nm¹³H-NMR: δ (ppm in DMSO-d₆)8.23 (s, 1H, C₈-H)8.17 (s, 1H, C₂-H)5 7.32 (s, 2H, C₆-NH₂, D₂O-exchange)6.36 (d, 1H, C₄-H, J = 3.8 Hz)5.75 (t, 1H, C₂-H, J = 5.7 Hz)5.32 (t, 1H, C₂-CH₂OH, D₂O-exchange)4.50 (d, 1H, C₅-H, J = 10.2 Hz)10 4.35 (dd, 1H, C₅-H, J = 4.1 Hz and 10.0 Hz)3.73 (m, 1H, C₂-CH₂OH)3.43 (m, 1H, C₂-CH₂OH)¹³C-NMR: δ (ppm in DMSO-d₆)

165.53, 153.12, 149.40, 139.30, 119.00, 87.99,

15 74.70, 63.29 and 60.51

Example 15Cis-2-hydroxymethyl-4-(adenin-9'-yl)-3-oxo-1,3-oxathiolane

(XIV)

20 A solution of 2-hydroxymethyl-4-(adenin-9'-yl)-1,3-oxathiolane (60 mg) in methanol (30 ml) was cooled at 0°C in an ice bath and meta-chloroperbenzoic acid (49 mg) was added slowly under stirring. The mixture was kept at this temperature for and solvent was evaporated under

25 reduced pressure. The residue was triturated with diethyl ether (2 x 15 ml) and purified on silica gel using EtOAc:MeOH (9:1) as eluant to give 49 mg of the product (77% yield). Surprisingly, only one diastereomer was formed. The product was characterized by H- and ¹³C-

30 NMR.

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

69

UV: (H₂O) Lambda max: 258 nm


m.p.: Dec >192°C

¹H-NMR: δ(ppm in DMSO-d₆)

- 5 8.24 (s, 1H, C₈-H)
 8.08 (s, 1H, C₂-H)
 7.41 (s, 2H, C₄-NH₂, D₂O-exchange)
 5.85 (d, 1H, C₄-H, J = 3.8 Hz)
 5.52 (t, 1H, C₂-CH₂OH, D₂O-exchange)
10 5.17 (d, 1H, C₅-H, J = 11.6 Hz)
 4.62 (dd, 1H, C₅-H, J = 4.1 and 11.8 Hz)
 4.60 (t, 1H, C₂-H, J = 3.6 Hz)
 4.02 (m, 1H, C₂-CH₂OH)
 3.82 (m, 1H, C₂-CH₂OH)

¹³C-NMR: δ(ppm in DMSO-d₆)

- 15 156.66, 153.51, 149.83, 138.56, 118.61, 111.84,
 75.99, 71.91 and 58.29

Example 16Cis-2-hydroxymethyl-4-(6'-N-methylamino-purin-9'-yl)-1,3-oxathiolane

- 25 A solution of cis-2-hydroxymethyl-4-(6'-chloropurin-9'-yl)-1,3-oxathiolane (144 mg) in ethanol (30 ml) was cooled at 0°C in an ice bath and methylamine gas was bubbled through the solution for 20 minutes. The mixture was placed in steel bomb and heated overnight at 110-115°C (16 hours). The bomb was cooled to room temperature and emptied. The mixture was evaporated in

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

70

vacuo and the residue was purified by chromatography on silica gel using EtOAc:MeOH (9:1) as eluant to give 102 mg (72%) of the desired product.

m.p.: 190-192°C

5 R_f: 0.43 (EtOAc:MeOH)

UV: (H₂O) Lambda max: 266 nm

¹H-NMR: δ(ppm in DMSO-d₆)

8.31 (s, 1H, C₈-H)

8.25 (s, 1H, C₂-H)

10 7.79 (b, 1H, C₄-NH)

6.38 (d, 1H, C₄-H, J = 3.8 Hz)

5.40 (t, 1H, C₂-CH₂-OH)

5.33 (t, 1H, C₂-H, J = 4.3 Hz)

4.64 (d, 1H, C₅-H, J = 10.5 Hz)


15 4.10 (dd, 1H, C₅-H, J = 4.3 and 10.5 Hz)

3.82 (m, 2H, C₂-CH₂-OH)

2.95 (s, 3H, C₄-NCH₃)

Example 17

20 Cis- and trans-2-hydroxymethyl-4-(6'-dimethylamino purin-9'-yl)-1,3-oxathiolane



cis-isomer:

A solution of cis-2-benzoyloxymethyl-4-(6'-chloropurin-9'-yl)-1,3-oxathiolane (300 mg) in ethanol (60 ml) was cooled at 0°C in an ice bath and dimethylamine gas was bubbled through the solution for 20 minutes. The mixture was placed in a steel bomb and heated overnight at 110-115°C (16 hours). The bomb was cooled to room temperature and emptied. Solvent was removed in vacuo and the residue was purified by

25

30

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

71

chromatography on silica gel using ethyl acetate as eluant to give 170 mg (76%) of the desired product.

m.p.: 124-126°C

R_f: 0.32 (EtOAc)

5 UV: (CH₃OH) Lambda max: 273 nm

¹H-NMR: δ(ppm in DMSO-d₆)

8.32 (s, 1H, C₈, -H)

8.22 (s, 1H, C₂, -H)

6.37 (d, 1H, C₄, -H, J = 4.0 Hz)

10 5.38 (t, 1H, C₂-CH₂OH, D₂O-exchange)

5.32 (t, 1H, C₂-H, J = 4.3 Hz)

4.63 (d, 1H, C₅-H, J = 11.5 Hz)

4.08 (dd, 1H, C₅-H, J = 4.0 and 10.5 Hz)

3.80 (m, 2H, C₂-CH₂OH)

15 3.43 (b, 6H, C₆, -N(CH₃)₂)

trans-isomer:

A solution of trans-2-benzoyloxymethyl-4-(6'-chloropurin-9'-yl)-1,3-oxathiolane (500 mg) in ethanol (70 ml) was cooled at 0°C in an ice bath and

20 dimethylamine gas was bubbled through the solution for 20 minutes. The mixture was placed in a steel bomb and heated overnight at 110°-115°C (16 hours). The bomb was cooled to room temperature and emptied. Solvent was removed in vacuo and the solid residue triturated with

25 diethylether (2 x 30 ml) and recrystallized in ethanol to give 268 mg of the desired product (72% yield).

m.p.: 174-176°C

R_f: 0.30(EtOAc)

UV: (CH₃OH) Lambda max: 271 nm

30 ¹H-NMR: δ(ppm in DMSO-d₆)

8.23 (s, 1H, C₈, -H)

8.22 (s, 1H, C₂, -H)

6.36 (d, 1H, C₄-H, J = 3.0 Hz)

5.71 (dd, 1H, C₂H, J = 4.9 and 6.8 Hz)

35 5.30 (t, 1H, C₂-CH₂OH, D₂O-exchange)


4.46 (dd, 1H, C₅-H, J = 3.3 and 12.4 Hz)

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

72

4.32 (dd, 1H, C₅-H, J = 4.3 and 10.4 Hz)3.68 (m, 1H, C₂-CH₂OH)3.43 (m, 7H, C₂-CH₂OH and C₆, -N(CH₃)₂)Example 185 Cis- and trans-2-benzoyloxymethyl-4-(2'-amino-6'-chloro-purin-9-yl)-1,3-oxathiolane

A mixture of 2-amino-6-chloropurine (6-chloroguanine, 1.3 g), ammonium sulfate (50 mg), and
10 hexamethyldisilazane (HMDS, 30 ml) became clear
(3 hours). Excess reagent was evaporated in vacuo and
the remaining volatile removed under high vacuum (1
hour). The residue was dissolved in dry dichloroethane
(75 ml) and a solution of 2-benzoyloxymethyl-4-acetoxy-
15 1,3-oxathiolane (1.1 g), in dry dichloroethane (20 ml)
was added under argon, followed by a solution of
trimethylsilyl trifluoromethane sulfonate (1.5 ml) in dry
dichloroethane (15 ml). The mixture was heated at
20 refluxing under argon for 2 hours, cooled to room
temperature and poured into saturated aqueous NaHCO₃
solution. After stirring for 15 minutes the organic
layer was collected and the aqueous phase was extracted
with methylene chloride (3 x 75 ml). The combined
organic layer was washed with water (2 x 100 ml), then
25 with brine solution, dried over MgSO₄, and filtered. The
filtrate was evaporated in vacuo and the residue was
purified by chromatography on silica gel using

SUBSTITUTE SHEET

WO 92/08717

73

PCT/CA91/00407

hexane:ethyl acetate (1:1) as eluant to give 460 mg of a fast moving product which was identified as trans-isomer and 340 mg of low moving product which was identified as cis-isomer. The total yield was 52%.

5 cis-isomer:

m.p.: 192-194°C

 R_f : 0.50 (hexane:ethyl acetate 3:7) $^1\text{H-NMR}$: δ (ppm in DMSO-d_6)

- 8.20 (s, 1H, C_8 , -H)
10 7.89 (m, 2H, aromatic)
7.69 (m, 1H, aromatic)
7.52 (m, 2H, aromatic)
7.03 (s, 2H, C_2 , - NH_2)
6.26 (d, 1H, C_4 -H, $J = 3.9$ Hz)
15 5.66 (t, 1H, C_2 -H, $J = 6.00$ Hz)
4.88 (d, 1H, C_5 -H, $J = 10.8$ Hz)
4.73 (m, 2H, C_2 - $\text{CH}_2\text{OOC}\text{C}_6\text{H}_5$)
4.16 (dd, 1H, C_5 -H, $J = 4.2$ and 10.7 Hz)

trans-isomer:

20 m.p.: 186-188°C

 R_f : 963 (hexane:ethyl acetate) $^1\text{H-NMR}$: δ (ppm in DMSO-d_6)


- 8.21 (s, 1H, C_8 , -H)
8.01 (m, 2H, aromatic)
25 7.60 (m, 1H, aromatic)
7.57 (m, 2H, aromatic)
7.04 (s, 2H, C_2 , - NH_2)
6.29 (d, 1H, C_4 -H, $J = 4.0$ Hz)
6.11 (dd, 1H, C_2 -H, $J = 3.2$ and 8.2 Hz)
30 4.63 (m, 2H, C_5 -H and C_2 - $\text{CH}_2\text{OOC}\text{C}_6\text{H}_5$)
4.38 (m, 2H, C_5 -H and C_2 - $\text{CH}_2\text{OOC}\text{C}_6\text{H}_5$)

SUBSTITUTE SHEET.

WO 92/08717

PCT/CA91/00407

74

Example 19Cis- and trans-2-hydroxymethyl-4-(2'-amino-6'-chloropurin-9'-yl)-1,3-oxathiolane

(XXXIX)

5 cis-isomer:

A solution of cis-2-benzoyloxymethyl-4-(2'-amino-6'-chloropurin-9'-yl)-1,3-oxathiolane (305 mg) in methanolic ammonia (100 ml) was stirred overnight at room temperature (16 hours). The mixture was evaporated under reduced pressure and the residue was triturated with diethyl ether (2 x 30 ml). The solid residue was recrystallized in ethanol to give pure 184 mg of product (82% yield).

m.p.: 194-196°C

15 R_f : 0.58 (EtOAc)UV: (CH₃OH) λ_{max} : 309 and 248 nm¹H-NMR: δ (ppm in DMSO-d₆)8.30 (s, 1H, C₈-H)7.03 (s, 2H, C₂-NH₂)20 6.19 (d, 1H, C₄-H, J = 3.9 Hz)5.41 (t, 1H, C₂-CH₂OH, D₂O-exchange)5.33 (t, 1H, C₂-H, J = 4.1 Hz)4.70 (d, 1H, C₅-H, J = 10.4 Hz)4.06 (dd, 1H, C₅-H, J = 4.1 and 10.5 Hz)25 3.82 (t, 2H, C₂-CH₂OH)trans-isomer:

A solution of trans-2-benzoyloxymethyl-4-(2'-amino-6'-chloropurin-9'-yl)-1,3-oxathiolane (150 mg) in

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

75

methanolic ammonia (50 ml) was stirred overnight at room temperature (16 hours). Solvent was evaporated under reduced pressure and the residue purified by chromatography on silica gel using ethyl acetate as eluant to give 83 mg (76%) of pure product.

m.p.: 180-182°C

R_f: 0.50 (ethyl acetate)


U.V. (CH₃OH) Lambda max: 309.5 and 248 nm

¹H-NMR: δ(ppm in DMSO-d₆)

- 10 8.21 (s, 1H, C₈-H)
 7.03 (s, 2H, C₂, -NH₂)
 6.20 (dd, 1H, C₄-H, J = 1.6 and 4.3 Hz)
 5.74 (dd, 1H, C₂-H, J = 4.7 and 8.9 Hz)
 5.31 (t, 1H C₂-CH₂OH, D₂O-exchange)
15 4.52 (dd, 1H, C₅-H, J = 1.7 and 10.4 Hz)
 4.31 (dd, 1H, C₅-H, J = 4.4 and 10.4 Hz)
 3.68 (g, 1H, C₂-CH₂OH)
 3.44 (g, 1H, C₂-CH₂OH)

Example 20

20 Cis- and trans-2-hydroxymethyl-4-(2',6'-diaminopurin-9'-yl)-1,3-oxathiolane



cis-isomer:

A mixture of cis-2-benzoyloxymethyl-4-(2'-amino-6'-chloropurin-9'-yl)-1,3-oxathiolane (175 mg) in saturated methanolic ammonia (50 ml) was placed in a steel bomb and heated overnight at 110-115°C (16 hours). The bomb was cooled to room temperature and emptied. The

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

76

mixture was evaporated to dryness and the solid residue triturated with diethyl ether (2 x 30 ml) and dissolved in methanol (100 ml). The solution was boiled with charcoal (2 g) for 5 minutes and filtered. The filtrate was evaporated in vacuo and the residue recrystallized in ethanol to give 90 mg of the product (75% yield).

m.p.: Dec. >250°C

R_f: 0.27 (EtOAc:MeOH 9:1)

UV: (CH₃OH) Lambda max: 281 and 258 nm

¹H-NMR: δ(ppm in DMSO-d₆)

7.80 (s, 1H, C₈-H)

6.94 (b, 2H, C₂-NH₂, D₂O-exchange)

6.12 (d, 1H, C₄-H, J = 3.9 Hz)

6.00 (b, 2H, C₆-NH₂, D₂O-exchange)

5.40 (b, 1H, C₂-CH₂OH, D₂O-exchange)

5.30 (t, 1H, C₂-H, J = 4.5 Hz)

4.61 (d, 1H, C₅-H, J = 10.4 Hz)

4.05 (dd, 1H, C₅-H, J = 4.2 and 10.4 Hz)

3.78 (m, 2H, C₂-CH₂OH)

trans-isomer:

A mixture of trans-2-benzoyloxymethyl-4-(2'-amino-6'-chloropurin-9'-yl)-1,3-oxathiolane (300 mg) in saturated methanolic ammonia (60 ml) was placed in a steel bomb and heated overnight at 110-115°C. The bomb was cooled to room temperature and emptied. The mixture was evaporated to dryness and the solid residue was triturated with diethyl ether (2 x 30 ml) and dissolved in methanol (100 ml). The solution was boiled with charcoal for 5 minutes and filtered. The filtrate was evaporated in vacuo and the residue was recrystallized in ethanol to give 149 mg (72%) of the desired product.

m.p.: 242-244°C

R_f: 0.23 (EtOAc:MeOH 9:1)

UV: (CH₃OH) Lambda max: 281 and 259 nm

¹H-NMR: δ(ppm in DMSO-d₆)

7.81 (s, 1H, C₈-H)


SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

77

- 5
6.78 (s, 2H, C₂,-NH₂, D₂O- xchange)
6.12 (d, 1H, C₄-H, J = 4.4 Hz)
5.90 (s, 2H, C₆,-NH₂,, D₂O-exchange)
5.70 (dd, 1H, C₂-H, J = 4.5 and 6.7 Hz)
5.31 (t, 1H, C₂-CH₂OH, D₂O-exchange)
4.44 (d, 1H, C₅,-H, J = 10.2 Hz)
4.29 (dd, 1H, C₅-H, J = 4.6 and 10.2 Hz)
3.67 (m, 1H, C₂-CH₂OH)
3.43 (m, 1H, C₂-CH₂OH)

10 Example 21Cis-2-hydroxymethyl-4-(guanine-9'-yl)-1,3-oxathiolane

- A mixture of cis-2-hydroxymethyl-4-(2'-amino-6'-chloropurin-9'-yl)-1,3-oxathiolane (100 mg), sodium
15 hydroxide (3 g), water (5 ml) and methanol (20 ml) was heated overnight at refluxing (16 hours) and cooled to room temperature. The mixture was diluted with water (100 ml), neutralized with ion-exchange resin (in pyridinium form) and filtered. The residue was washed
20 with water (100 ml), the combined aqueous solution evaporated in vacuo and the residue recrystallized in water ethanol to give 48 g (51%) the desired product.
m.p.: Dec>280°C

- UV: (H₂O) Lambda max: 270 and 250 nm
25 ¹H-NMR: δ(ppm in DMSO-d₆)
10.67 (b, 1H, -NH)
7.86 (s, 1H, C₈,-H)
6.55 (b, 2H, C₂,-NH₂, D₂O- xchange)


SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

78

- 6.06 (d, 1H, C₄-H, J = 3.9 Hz)
 5.40 (b, 1H, C₂-CH₂OH, D₂O-exchange)
 5.29 (t, 1H, C₂-H, J = 4.6 Hz)
 4.61 (d, 1H, C₅-H, J = 10.4 Hz)
 5 4.05 (dd, 1H, C₅-H, J = 4.4 and 10.8 Hz)
 3.79 (m, 2H, C₂-CH₂OH)

Example 222-benzoyloxymethyl-1,3-dithiolane

(XIX)

- 10 A mixture of 2-benzoyloxyacetaldehyde (5.65 g),
 1,2-ethanedithiol (3 ml) and paratoluenesulfonic acid
 (200 mg) in toluene (250 ml) was heated at refluxing
 under water removal conditions using a Dean Stark
 apparatus for 4 hours. The mixture was cooled to room
 15 temperature, washed first with saturated aqueous NaHCO₃
 solution (1 x 60 ml), then with water (2 x 60 ml), and
 dried over reduced pressure. The residue was purified by
 chromatography on silica gel using hexane:ethyl acetate
 (9:1) as eluant to give 5.2 g of pure product which was
 20 characterized by ¹H- and ¹³C-NMR spectroscopy.

¹H-NMR: δ (ppm in CDCl₃)

- 8.07 (m, 2H, aromatic)
 7.59 (m, 1H, aromatic)
 7.44 (m, 2H, aromatic)
 25 4.75 (t, 1H, C₂-H)
 4.36 (d, 2H, C₂-CH₂OOC(=O)C₆H₅)
 3.24 (s, 4H, C₄-H and C₅-H)

¹³C-NMR: δ (ppm in CDCl₃)


SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

79

166.27, 133.30, 129.85, 128.53, 68.15, 50.46 and 37.87

Example 232-benzoyloxymethyl-3-oxo-1,3-dithiolane

(XX)

2-Benzoyloxymethyl-1,3-dithiolane (5.2 g) was dissolved in dry methylene chloride (200 ml) and cooled to 0°C in an ice bath. Meta-chloroperbenzoic acid (80%, 4.67 g) in methylene chloride (100 ml) was added slowly while under stirring. The mixture was stirred at room temperature for 1 hour and then poured with into saturated aqueous NaHCO₃ solution (100 ml). The organic layer was separated, washed first with saturated NaHCO₃ solution (2 x 100 ml), then with water (100 ml), and finally with brine solution (100 ml), dried over MgSO₄ and filtered. The filtrate was evaporated in vacuo and the residue purified by chromatography on silica gel using ethyl acetate as eluant to give 4.0 g (74%) of pure product as a mixture cis- and trans-isomers.

¹H-NMR: δ(ppm in CDCl₃)

8.09 (m, 2H, aromatic)
7.60 (m, 1H, aromatic)
7.46 (m, 2H, aromatic)
4.82 (dd, 1H, C₂-H, trans-isomers)
4.57 (m, 2H, C₂-CH₂OOCC₆H₅)
4.32 (dd, 1H, C₂-H, cis-isomer)
3.78 (m, 1H, C₄-H, trans-isomer)
3.59 (m, 2H, C₅-H, cis- and trans-isomer)
3.41 (m, 1H, C₄-H, cis-isomer)

SUBSTITUTE SHEET.

WO 92/08717


80

PCT/CA91/00407

2.87 (m, 1H, C₄-H, cis- and trans-isomer)

Example 24

Cis- and trans-2-benzoyloxymethyl-4-acetoxy-1,3-
dithiolane



(XXI)

A mixture of 2-benzoyloxymethyl-3-oxo-1,3-dithiolane (5.1 g), sodium acetate (65 g) and acetic anhydride (100 ml) was heated at refluxing for 3 hours. Excess reagent was removed under reduced pressure. The residue was dissolved in methylene chloride (200 ml), washed first with saturated aqueous NaCO₃ solution (3 x 100 ml), then with water (100 ml), and finally with brine solution (100 ml), dried over MgSO₄, and filtered. The filtrate was evaporated in vacuo and the residue purified by chromatography on silica gel using hexane:ethyl acetate (9:1) as eluant. The desired product was a byproduct and obtained in 9% yield (535 mg) as a mixture cis- and trans-isomer which was characterized by spectroscopic methods.

cis-isomer:

¹H-NMR: δ(ppm in CDCl₃)

8.01 (m, 2H, aromatic)

7.54 (m, 1H, aromatic)

7.41 (m, 2H, aromatic)

6.51 (t, 1H, C₄-H)

4.79 (t, 1H, C₂-H)

4.39 (dd, 1H, C₂-CH₂OOCOC₆H₅)

SUBSTITUTE SHEET

WO 92/08717

81

PCT/CA91/00407


4.26 (dd, 1H, C₂-CH₂OOCCH₅)
3.34 (m, 2H, C₅-H)
2.05 (s, 3H, CH₃)

trans-isomer:

5 ¹H-NMR: δ(ppm in CDCl₃)
8.04 (m, 2H, aromatic)
7.57 (m, 1H, aromatic)
7.42 (m, 2H, aromatic)
6.56 (t, 1H, C₄-H)
10 4.85 (t, 1H, C₂-H)
4.53 (m, 2H, C₂-CH₂OOCCH₅)
3.43 (d, 2H, C₅-H)
2.08 (s, 3H, CH₃)

Example 25

15 Cis- and trans-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-dithiolane



(XXII)

20 A mixture of cytosine (500 mg), ammonium sulfate (20 mg) and hexamethyldisilazane (15 ml) was heated at refluxing under argon until the solution became clear (3 hours). Excess reagent was evaporated under reduced pressure. The residue was dried under high vacuum for 1 hour and dissolved in dry methylene chloride
25 (40 ml). A solution of 2-benzoyloxymethyl-4-acetoxy-1,3-dithiolane (882 mg) in dry methylene chloride (30 ml) was added under argon and the mixture was cooled at -10°C in an ice-salt bath. A solution of SnCl₄ (0.52 ml) in

SUBSTITUTE SHEET

WO 92/08717


PCT/CA91/00407

82

methylene chloride (50 ml) was added and the mixture was stirred for 30 minutes and then heated overnight at refluxing (16 hours). The mixture was cooled to room temperature and poured into aqueous NaHCO_3 solution (100 ml). The organic layer was collected and the aqueous layer extracted with methylene chloride (2 x 100 ml) and filtered over celite. The combined organic layer was washed with water (2 x 100 ml), dried over MgSO_4 , filtered and evaporated under reduced pressure. The residue was purified by chromatography on silica gel using ethyl acetate:methanol (9:1) as eluant to give 335 mg (32%) of the product in as a mixture of cis- and trans-isomers in a ratio of 1:1.2. The product was separated in next step as N-acetyl derivatives.

15 Example 26

Cis- and trans-2-benzoyloxymethyl-4-(N₄-acetyl cytosin-1'-yl)-1,3-dithiolane



(XXIII)

A solution cis- and trans-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-dithiolane (170 mg), 4-dimethylaminopyridine (20 mg), and acetic anhydride (0.1 ml) in dry pyridine (15 ml) was stirred overnight at room temperature (16 hours) and then poured into cold water (100 ml). The mixture was extracted with methylene chloride (3 x 75 ml), and the combined organic layer was washed with water (3 x 100 ml), dried over MgSO_4 and filtered. The filtrate was evaporated in vacuo and the

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

83

residue was purified by chromatography on silica gel using thyl acetate as eluant to give pure trans-2-benzoyloxymethyl-4-(N₄, -acetyl cytosin-1'-yl)-1,3-dithiolane as the fast moving spot and pure cis-2-benzoyloxymethyl-4-(N₄, -acetyl cytosin-1'-yl)-1,3-dithiolane as the lower moving product. The two isomers were characterized by spectroscopic methods.

cis-isomer:¹H-NMR: δ(ppm in CDCl₃)

10	9.51 (s, 1H, C ₄ , -NH-COCH ₃)
	8.49 (d, 1H, C ₆ , -H, J = 7.6 Hz)
	8.04 (m, 2H, aromatic)
	7.60 (m, 1H, aromatic)
	7.45 (m, 2H, aromatic)
15	7.29 (d, 1H, C ₅ , -H, J = 7.6 Hz)
	6.70 (d, 1H, C ₄ -H, J = 1.7 Hz)
	4.99 (t, 1H, C ₂ -H, J = 2.6 Hz)
	4.76 (m, 2H, C ₂ -CH ₂ OOCC ₆ H ₅)
	3.61 (dd, 1H, C ₅ -H, J = 4.2 and 13.5 Hz)
20	3.45 (d, 1H, C ₅ -H, J = 13.2 Hz)
	2.25 (s, 3H, CH ₃)

trans-isomer:¹H-NMR: δ(ppm in CDCl₃)


	9.50 (s, 1H, C ₄ , -NH-COCH ₃)
25	8.24 (d, 1H, C ₆ , -H, J = 7.6 Hz)
	8.03 (m, 2H, aromatic)
	7.61 (m, 1H, aromatic)
	7.46 (m, 3H, C ₅ , -H and aromatic)
	6.76 (d, 1H, C ₄ -H, J = 3.6 Hz)
30	5.02 (t, 1H, C ₂ -H, J = 7.2 Hz)
	4.49 (dd, 1H, C ₂ -CH ₂ OOCC ₆ H ₅ , J = 7.1 and 11.4 Hz)
	4.37 (dd, 1H, C ₂ -CH ₂ OOCC ₆ H ₅ , J = 7.2 and 11.4 Hz)
	3.62 (dd, 1H, C ₅ -H, J = 4.2 and 13 Hz)
	3.43 (d, 1H, C ₅ -H, J = 14.5 Hz)
35	2.26 (s, 3H, CH ₃)

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

84

Example 27Cis- and trans-2-hydroxymethyl-4-(cyt sin-1'-yl)-1,3-dithiolane

(XXIV)

5 cis-isomer:

A solution of cis-2-benzoyloxymethyl-4-(N₄,'-acetyl cytosin-1'-yl)-1,3-dithiolane (10 mg) in methanolic ammonia (20 ml) was overnight stirred at room temperature (16 hours). The mixture was evaporated under reduced pressure and the residue purified by chromatography on silica gel using ethyl acetate:methanol (4:1) as eluant to give 3 mg (47%) of the desired product as a foam.

trans-isomer:

15 A solution of trans-2-benzoyloxymethyl-4-(N₄,'-acetyl cytosin-1'-yl)-1,3-dithiolane (35 mg) in methanolic ammonia (20 ml) was stirred overnight at room temperature. The mixture was evaporated under reduced pressure and the residue was triturated with diethyl ether (2 x 10 ml) to give the desired product in 90% yield.

m.p.: 198-200°C

UV: (CH₃OH) Lamda max: 270 nm¹H-NMR: δ(ppm in DMSO-d₆):

- 25 7.91 (d, 1H, C₆, -H, J = 7.5 Hz)
7.19 (d, 2H, C₄, -NH₂, D₂O-exchange)
6.49 (d, 1H, C₄, -H, J = 3.0 Hz)
5.71 (d, 1H, C₅, -H, J = 7.5 Hz)

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

85

5.38 (t, 1H, C₂-CH₂OH, D₂O-exchange)4.75 (t, 1H, C₂-H, J = 6.9 Hz)3.40 (m, 4H, C₅-H and C₂-CH₂OH)¹³C-NMR: δ(ppm in DMSO-d₆):

5 171.60, 160.93, 148.39, 98.86, 73.64, 71.56, 60.66
 and 48.01

Example 28Antiviral Activity: MT-4 Formazan Assay

Anti-HIV-1 antiviral activity was determined in
10 MT-4 cells. A suspension of cells (approximately 10⁶
cells/ml) in RPMI 1640 growth medium was infected with
HIV-1 strain RF at a M.O.I. of 10⁻³ infectious
units/cell. An uninfected cell suspension was prepared
in parallel to evaluate drug-induced cytotoxicity. The
15 two suspensions were incubated for 90 minutes at room
temperature. Test compounds were serially diluted in 10-
fold decrements from 100 µg/ml to 0.01 µg/ml (final
concentrations in two 96 well microtitre plates. 20 µl
of infected cell suspension were inoculated into each
20 well of one of the plates (anti-viral), while 20 µl of
uninfected cell suspension were added to each well of the
second plate (cytotoxicity). The plates were then
incubated for 7 days at 37°C. After incubation, 10 µl of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
25 bromide (MTT) at 20 mg/ml was added to all wells and the
plates incubated for a further 90 minutes at 37°C.
150 µl of 10% (v/v) alcoholic Triton X-100 was
then added and the cells resuspended. After 15 minutes
at room temperature, the plates were analyzed in a
30 Multiskan MC reader at 405 nm. Conversion of yellow MMT
to its formazan derivative is maximum in uninfected
cells, and absent in untreated infected cells. The
optical density values for the cytotoxicity controls and
the antiviral test wells were graphically plotted and the
35 dose of compounds required to inhibit the conversion of

SUBSTITUTE SHEET,

WO 92/08717

PCT/CA91/00407

86

MMT to 50% of the untreated uninfected controls was calculated. In this way, both the 50% cytotoxic dose (CD 50%) and the 50% anti-viral dose (ID 50%) can be calculated. Table 1 shows CD 50% and ID 50% values
5 obtained for cis-2-hydroxymethyl-4-(adenosine-9'-yl)-1,3-oxathiolane and 2',3'-dideoxyinosine.

Table 1

<u>Compound</u>		<u>CD 50%</u>	<u>ID 50%</u>
	<u>cis</u> -XIII	100 µg/ml	2.1 µg/ml
10	ddI	100 µg/ml	2.3 µg/ml

SUBSTITUTE SHEET


WO 92/08717

PCT/CA91/00407

87

CLAIMS:

1. A compound of formula (I), the geometric and optical isomers thereof, and mixtures of those isomers:



(I)

wherein:

X is selected from the group consisting of S , $S=O$, and SO_2 ;

Y is selected from the group consisting of O , S , $S=O$, and SO_2 ;

R_1 is hydrogen; and

R_2 is a purine or pyrimidine base or an analogue or derivative thereof; and
pharmaceutically acceptable derivatives thereof.

2. The compound according to claim 1 wherein Y is O .

3. The compound according to claim 1 wherein Y is S , $S=O$ or SO_2 .


















4. The compound of formula (I) according to claim 1 wherein R_2 is selected the group consisting of:

SUBSTITUTE SHEET

WO 92/08717

88

PCT/CA91/00407




SUBSTITUTE SHEET

WO 92/08717

89

PCT/CA91/00407




SUBSTITUTE SHEET.

WO 92/08717

PCT/CA91/00407

90



wherein:

R₃ is selected from the group consisting of hydrogen, C₁₋₁₀ acyl, hydroxyl, substituted or unsubstituted C₁₋₆ alkyl, and substituted or unsubstituted C₁₋₆ alkenyl or alkynyl;

R₄ and R₅ are independently selected from the group consisting of hydrogen, hydroxymethyl, trifluoromethyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₁₋₆ alkenyl or alkynyl, bromine, chlorine, fluorine, iodine, and thioaryl;

R₆ is selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, cyano, carboxy, carboxamide, ethoxycarbonyl, carbamoyl, and thiocarbamoyl;

R₇ and R₈ are independently selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, substituted or unsubstituted amino, and hydroxy; and

SUBSTITUTE SHEET


WO 92/08717

PCT/CA91/00407

91

R_9 is selected from the group consisting of hydrogen, C_{1-10} acyl, hydroxyl, substituted or unsubstituted C_{1-6} alkyl, and substituted or unsubstituted C_{1-6} alkenyl or alkynyl.

- 5 5. The compound according to claim 4 wherein R_2 is




wherein:

- R_7 and R_8 are independently selected from the group consisting of hydrogen, bromine, chlorine, fluorine,
10 iodine, substituted or unsubstituted amino, and hydroxy.

6. The compound according to any one of claims 1 to 5 in the form of its cis isomer.

7. A compound of formula (Ia), the geometric and optical isomers thereof, and mixtures of those
15 isomers:



(Ia)

wherein:

X is selected from the group consisting of S, S=O, and SO₂;

- 20 R_1 is hydrogen; and

















R_2 is selected from the group consisting of

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

92



SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

93

where in:

- R_3 is selected from the group consisting of hydrogen, C_{1-10} acyl, hydroxyl, substituted or unsubstituted C_{1-6} alkyl, and substituted or unsubstituted C_{1-6} alkenyl or alkynyl;


- R_4 and R_5 are independently selected from the group consisting of hydrogen, hydroxymethyl, trifluoromethyl, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{1-6} alkenyl or alkynyl, bromine, chlorine, fluorine, iodine, and thioaryl;

- R_6 is selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, cyano, carboxy, carboxamide, ethoxycarbonyl, carbamoyl, and thiocarbamoyl;

- R_7 and R_8 are independently selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, substituted or unsubstituted amino, and hydroxy; and

- R_9 is selected from the group consisting of hydrogen, C_{1-10} acyl, hydroxyl, substituted or unsubstituted C_{1-6} alkyl, and substituted or unsubstituted C_{1-6} alkenyl or alkynyl; and and pharmaceutically acceptable derivatives thereof.

8. A compound of formula (Ib), the geometric and optical isomers thereof, and mixtures of those isomers:



(Ib)

wherein:
















- each X is independently selected from the group consisting of S , $S=O$, and SO_2 ;

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

94


 R_1 is hydrogen; and R_2 is selected from the group consisting of

SUBSTITUTE SHEET

WO 92/08717

95

PCT/CA91/00407



wherein:

R_3 is selected from the group consisting of hydrogen, C_{1-10} acyl, hydroxyl, substituted or unsubstituted C_{1-6} alkyl, and substituted or unsubstituted C_{1-6} alkenyl or alkynyl;

R_4 and R_5 are independently selected from the group consisting of hydrogen, hydroxymethyl, trifluoromethyl, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{1-6} alkenyl or alkynyl, bromine, chlorine, fluorine, iodine, and thioaryl;

R_6 is selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, cyano, carboxy, carboxamide, ethoxycarbonyl, carbamoyl, and thiocarbamoyl;

R_7 and R_8 are independently selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, substituted or unsubstituted amino, and hydroxy; and

R_9 is selected from the group consisting of hydrogen, C_{1-10} acyl, hydroxyl, substituted or unsubstituted C_{1-6} alkyl, and substituted or unsubstituted C_{1-6} alkenyl or alkynyl; and and pharmaceutically acceptable derivatives thereof.

9. The compound according to claim 1 selected from the group consisting of:

cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(cytosin-1'-yl)-

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

96

1,3- xathiolan , and mixtures thereof;

cis-2-hydroxymethyl-4-(N₄'-acetyl-cyt sin-1'-yl)-
1,3-oxathiolane, trans-2-hydroxymethyl-4-(N₄'-acetyl-
cytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;

5 cis-2-hydroxymethyl-4-(uracil-1'-yl)-1,3-
oxathiolane, trans-2-hydroxymethyl-4-(uracil-1'-yl)-1,3-
oxathiolane, and mixtures thereof;

cis-2-hydroxymethyl-4-(thymine-1'-yl)-1,3-
oxathiolane, trans-2-hydroxymethyl-4-(thymine-1'-yl)-1,3-
10 oxathiolane, and mixtures thereof;

cis-2-hydroxymethyl-4-(6'-chloropurin-9'-yl)-1,3-
oxathiolane, trans-2-hydroxymethyl-4-(6'-chloropurin-9'-
yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-hydroxymethyl-4-(adenine-9'-yl)-1,3-
15 oxathiolane, trans-2-hydroxymethyl-4-(adenine-9'-yl)-1,3-
oxathiolane, and mixtures thereof;

cis-2-hydroxymethyl-3-oxo-4-(adenine-9'-yl)-1,3-
oxathiolane;

cis-2-hydroxymethyl-4-(6'-N-methylamino-purin-9'-
20 yl)-1,3-oxathiolane;

cis-2-hydroxymethyl-4-(6'-N,N-dimethylamino-purin-
9'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(6'-N,N-
dimethylamino-purin-9'-yl)-1,3-oxathiolane, and mixtures
thereof;

25 cis-2-hydroxymethyl-4-(2'-amino-6'-chloro-purin-9'-
yl)-1,3-oxathiolane, trans-2-hydroxymethyl-4-(2'-chloro-
amino-6'-purin-9'-yl)-1,3-oxathiolane, and mixtures
thereof;

cis-2-hydroxymethyl-4-(2',6'-diamino-purin-9'-yl)-
30 1,3-oxathiolane, trans-2-hydroxymethyl-4-(2',6'-diamino-
purin-9'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-hydroxymethyl-4-(guanine-9'-yl)-1,3-
oxathiolane;

cis-2-hydroxymethyl-4-(cytosine-1'-yl)-1,3-
35 dithiolane, trans-2-hydroxymethyl-4-(cytosine-1'-yl)-1,3-
dithiolan , and mixtures thereof;

SUBSTITUTE SHEET

WO 92/08717

PCT/CA91/00407

97

cis-2-hydroxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-dithiolane, trans-2-hydroxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-dithiolane, and mixtures thereof; and pharmaceutically acceptable derivatives thereof in the form of a racemic mixture or single enantiomer.

10. The compound according to claim 9 selected from the group consisting of:

cis-2-hydroxymethyl-4-(adenin-9'-yl)-1,3-oxathiolane; and
pharmaceutically acceptable derivatives thereof in the form of a racemic mixture or single enantiomer.

11. The compound according to any one of claims 1, 7 or 8 in the form of a racemic mixture.

12. The compound according to any one of claims 1, 7 or 8 substantially in the form of a single enantiomer.

13. A pharmaceutical formulation effective against viral infections comprising a pharmaceutically effective amount of a compound according to any one of claims 1, 7 or 8 and a pharmaceutically acceptable carrier.

14. The pharmaceutical formulation according to claim 13 additionally comprising a further therapeutic agent.

15. A method of treating viral infections in mammals comprising the step of administering to said mammal the pharmaceutical formulation according to claim 13 or 14.

SUBSTITUTE SHEET

WO 92/08717


PCT/CA91/00407

98

16. The method according to claim 15, wherein said viral infection is caused by human immunodeficiency virus and said mammal is a human.

5 17. The method according to claim 15, wherein said viral infection is caused by hepatitis B virus and said mammal is a human.

18. An ester of formula (IV) the geometric and optical isomers thereof, and mixtures of those isomers:



10 wherein:

W is selected from the group consisting of PO_3^- , SPO_3^- ,

and $-\text{O}-\text{C}-(\text{CH}_2)_n-\text{C}-\text{O}-$ where n is an integer of 1 to 10;

J is any nucleoside or nucleoside analog or derivative thereof;

15 X is selected from the group consisting of S, S=O and SO_2 ,

Y is selected from the group consisting of O, S, S=O, and SO_2 ; and

20 R_2 is a purine or pyrimidine base or analogue or derivative thereof.

19. The ester according to claim 18 wherein J is:


SUBSTITUTE SHEET
ISA/EP

WO 92/08717

PCT/CA91/00407

99

20. An intermediate of formula (Ic), the geometric and optical isomers thereof, and mixtures of those isomers, useful for the production of substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties:



(Ic)

wherein:

X is selected from the group consisting of S, S=O, and SO₂;

Y is selected from the group consisting of O, S, S=O, and SO₂;

R₁ is selected from the group consisting of trisubstituted silyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted aralkyl, and substituted or unsubstituted C₁₋₁₆ acyl; and

R₂ is a purine or pyrimidine base or an analogue or derivative thereof.

21. The intermediate according to claim 20 wherein R₁ is selected from the group consisting of benzyl, trityl, benzoyl and a benzoyl which may be substituted in any position by at least one group selected from the group consisting of bromine, chlorine, fluorine, iodine, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro and trifluoromethyl.

22. The intermediate according to claim 20 useful for the production of substituted 1,3-oxathiolanes with antiviral properties selected from the group consisting of:

SUBSTITUTE SHEET
ISA/EP

WO 92/08717

PCT/CA91/00407

100

cis-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-4-(uracil-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(uracil-1'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-4-(thymin-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(thymin-1'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-4-(6'-chloropurin-9'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(6'-chloropurin-9'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-4-(adenin-9'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(adenin-9'-yl)-1,3-oxathiolane;

cis-2-benzoyloxymethyl-4-(2'-amino-6'-chloro-purin-9'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-(2'-amino-6'-chloro-purin-9'-yl)-1,3-oxathiolane, and mixtures thereof.

23. The intermediate according to claim 20 useful for the production of substituted 1,3-dithiolanes with antiviral properties selected from the group consisting of:

cis-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-dithiolane, trans-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-dithiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-dithiolane, trans-2-benzoyloxymethyl-4-(N₄'-acetyl-cytosin-1'-yl)-1,3-dithiolane, and mixtures thereof;

cis-2-t-butyldiphenylsilyloxymethyl-4-(cytosin-1'-yl)-1,3-dithiolane, trans-2-t-butyldiphenylsilyloxy-

SUBSTITUTE SHEET
ISA/EP

WO 92/08717


PCT/CA91/00407

101

m thyl-4-(cytosin-1'-yl)-1,3-dithiolane, and mixtures thereof; and

cis-2-t-butyldiphenylsilyloxymethyl-4-(N₄'-acetoxy-cytosin-1'-yl)-1,3-dithiolane, trans-2-t-butyldiphenyl-silyloxymethyl-4-(N₄'-acetoxy-cytosin-1'-yl)-1,3-dithiolane, and mixtures thereof.

24. An intermediate of formula (Id), the geometric and optical isomers thereof, and mixtures of those isomers, useful for the production of substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties:



(Id)

wherein:

X is selected from the group consisting of S, S=O, and SO₂;

Y is selected from the group consisting of O, S, S=O, and SO₂;

R₄ is selected from the group consisting of trisubstituted silyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted aralkyl, and substituted or unsubstituted C₁₋₁₆ acyl; and

L is a leaving group.

25. The intermediate according to claim 24 wherein R₄ is selected from the group consisting of benzyl, trityl, benzoyl and a benzoyl which may be substituted in any position by at least one group selected from the group consisting of bromine,

SUBSTITUTE SHEET
ISA/EP

WO 92/08717

PCT/CA91/00407

102

chlorine, fluorine, iodine, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro and trifluoromethyl.

26. The intermediate according to claim 24 useful for the production of substituted 1,3-oxathiolanes with antiviral properties selected from the group consisting of:

2-benzoyloxymethyl-1,3-oxathiolane;

cis-2-benzoyloxymethyl-1-oxo-1,3-oxathiolane, trans-2-benzoyloxymethyl-1-oxo-1,3-oxathiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-4-acetoxy-1,3-oxathiolane, trans-2-benzoyloxymethyl-4-acetoxy-1,3-oxathiolane, and mixtures thereof;

27. The intermediate according to claim 24 useful for the production of substituted 1,3-dithiolanes with antiviral properties selected from the group consisting of:

2-t-butyldiphenylsilyloxymethyl-1,3-dithiolane;

2-benzoyloxymethyl-1,3-dithiolane;

cis-2-benzoyloxymethyl-3-oxo-1,3-dithiolane, trans-2-benzoyloxymethyl-3-oxo-1,3-dithiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-4-acetoxy-1,3-dithiolane, trans-2-benzoyloxymethyl-4-acetoxy-1,3-dithiolane, and mixtures thereof;

cis-2-t-butyldiphenylsilyloxymethyl-4-hydroxy-1,3-dithiolane, trans-2-t-butyldiphenylsilyloxymethyl-4-hydroxy-1,3-dithiolane, and mixtures thereof; and

cis-2-t-butyldiphenylsilyloxymethyl-4-acetoxy-1,3-dithiolane, trans-2-t-butyldiphenylsilyloxymethyl-4-acetoxy-1,3-dithiolane, and mixtures thereof.

SUBSTITUTE SHEET
ISA/EP


WO 92/08717

PCT/CA91/00407

103

28. A process for preparing a 1,3-oxathiolane compound of formula (Ia), the geometric and optical isomers thereof, and mixtures of those isomers:

(Ia)



5 wherein:

X is selected from the group consisting of S, S=O, and SO₂;


R₁ is hydrogen; and

10 R₂ is a purine or pyrimidine base or an analogue or derivative thereof;

the process comprising the steps of:

15 a) condensing an aldehyde having of the formula R₁OCH₂CHO, wherein R₁ is selected from the group consisting of trisubstituted silyl, substituted or unsubstituted C₁₋₆, alkyl, substituted or unsubstituted aralkyl, and substituted or unsubstituted C₁₋₆, acyl, with a mercaptoalcohol in an organic solvent containing an acid catalyst to produce an intermediate of the formula:

20



b) treating the intermediate of step (a) with a peracid to give a corresponding sulfoxide;


25 c) treating the intermediate of step (b) with an anhydride of the formula (R₂)₂O, wherein R₂ is substituted or unsubstituted C₁₋₆, alkyl, in the presence of a buffer to produce an intermediate of the formula:

SUBSTITUTE SHEET
ISA/EP

WO 92/08717

PCT/CA91/00407


104



wherein L is a leaving group;

- 5 d) treating the intermediate of step (c) with a silylated pyrimidine or purine base or analogue thereof, in the presence of a Lewis acid and hydrolyzing the R₁ function to produce a compound of the formula (Ia).

- 10 29. A process for preparing a 1,3-dithiolane compound of formula (Ib), the geometric and optical isomers thereof, and mixtures of those isomers:



(Ib)

wherein:

each X is independently selected from the group consisting of S, S=O, and SO₂;

- 15 R₁ is hydrogen; and

R₂ is a purine or pyrimidine base or an analogue or derivative thereof;

the process comprising the steps of:


- 20 a) condensing an aldehyde having of the formula R₁OCH₂CHO, wherein R₁ is selected from the group consisting of trisubstituted silyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted aralkyl, and substituted or unsubstituted C₁₋₆ acyl, with a vicinal dithiol in an organic solvent containing
25 an acid catalyst to produce an intermediate of the formula:

SUBSTITUTE SHEET
ISA/EP

WO 92/08717


PCT/CA91/00407

105



b) treating the intermediate of step (a) with a paracid to give a corresponding sulfoxide;

5 c) treating the intermediate of step (b) with an anhydride of the formula $(R_x)_2O$, wherein R_x is substituted or unsubstituted C_{1-6} alkyl, in the presence of a buffer to produce an intermediate of the formula:




wherein L is a leaving group;

10 d) treating the intermediate of step (c) with a silylated pyrimidine or purine base or analogue thereof containing an NH_2 group, in the presence of a Lewis acid;

15 e) acetylation of the NH_2 group and hydrolyzing the R_n function to produce a compound of the formula (Ib).

30. A process for preparing a 1,3-dithiolane compound of formula (Ib), the geometric and optical isomers thereof, and mixtures of those isomers:



(Ib)

wherein:

SUBSTITUTE SHEET
ISA/EP

WO 92/08717

PCT/CA91/00407

106

X is selected from the group consisting of S, S=O, and SO₂;


Y is selected from the group consisting of S, S=O, and SO₂;

5 R₁ is hydrogen; and


R₂ is a purine or pyrimidine base or an analogue or derivative thereof;

the process comprising the steps of:

10 a) reacting mercaptothioacetic acid with an aldehyde of formula R₁OCH₂CHO in an organic solvent in the presence of a Lewis acid to produce an intermediate of the formula:



15 b) reducing the intermediate of step (a) in an organic solvent and reacting the reduced intermediate with an acid anhydride or acid chloride in the presence of pyridine and an acetylation catalyst to give an intermediate of the formula:



wherein L is a leaving group;

20 c) treating the intermediate of step (b) with a silylated pyrimidine or purine in the presence of a Lewis acid and cleavage of the R₁ function to produce a compound of the formula (Ib).

SUBSTITUTE SHEET
ISA/EP

WO 92/08717

PCT/CA91/00407


107

31. The process for preparing a 1,3-dithiolane according to claim 30, wherein R_1 is a silyl protecting group.

SUBSTITUTE SHEET
ISA/EP

INTERNATIONAL SEARCH REPORT

International Application No. PCT/CA 91/00407

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁹		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.C1.5	C 07 D 409/04	C 07 D 411/04 C 07 D 473/02
A 61 K 31/505	C 07 F 7/18	
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.C1.5	C 07 D 409/00 C 07 D 411/00 C 07 D 473/00	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0382526 (J.A.F.) 16 August 1990, see the whole document -----	1-8, 11-14, 17
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
31-01-1992		17 FEB 1992
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer Mme N. KUIPER 

Form PCT/ISA/210 (second sheet) (January 1985)

International Application No. PCT/CA91/00407

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim numbers _____ because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 15 and 16 are directed to a method of treatment of the human body, the search has been based on the attributed effects of the compounds.

2. ☒ Claim numbers 18 (compounds of cl. 1) because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

2. ☐ Claim numbers _____ because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(e).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims: _____
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: _____
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

CA 9100407

SA 53007

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 11/02/92
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0382526	16-08-90	US-A- 5047407	10-09-91
		AU-A- 4920190	16-08-90
		CA-A- 2009637	08-08-90
		JP-A- 3007282	14-01-91

EPO FORM P0179

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82